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1 Summary 
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor that is characterized by 
abundant tumor stroma and a potent immunosuppressive microenvironment. Further studies to clarify 
why T cells infiltrate the tumor but are not able to perform effector functions as well as to find new 
effective therapies to overcome immunosuppression are urgently needed.  
 
The aims of the present study were (1) to characterize different murine PDAC tumor models in regard 
to their utility for studying novel immunotherapeutic approaches, (2) to assess the therapeutic efficacy 
of a novel bifunctional ppp-siRNA that combines silencing of the immunosuppressive molecule 
galectin-1 and RIG-I-mediated immune activation in murine PDAC and (3) to characterize the 
immunosuppressive mechanisms leading to T cell inhibition in the tumor microenvironment. 
 
(1) This study revealed that the pancreatic cancer cell line T110299, which was developed from a 
primary tumor of the KPC mouse model, is a new valuable tool for studying novel treatment strategies 
for PDAC. The histological appearance of T110299 tumors reflects in many aspects the primary 
tumors in KPC mice, which harbor mutations in the Kras oncogene and p53, and the human disease 
with regard to tumor differentiation, extensive tumor stroma development, poor vascularization and 
expression of immunosuppressive molecules, like indoleamine 2,3-dioxygenase (IDO) and galectin-1 
(Gal-1). In contrast, Panc02 tumors were found to have a sarcomatoid architecture with very little 
tumor stroma. In Panc02 cells, galectin-1 was strongly expressed by the tumor cells, which differs 
from the situation found in humans, KPC mice and T110299 tumors, where galectin-1 is preferentially 
expressed in tumor-associated pancreatic stellate cells (PSC). However, expression of the cytosolic 
helicase RIG-I was functional in Panc02 cells, but defective in T110299 cells. As RIG-I is expressed 
in all human PDAC cell lines tested, the Panc02 model appears to be better suited to study RIG-I-
based immunotherapies (Ellermeier et al., 2013). Thus, the histological and functional characterization 
of the tumor models in this thesis will allow selecting the best-suited tumor model for addressing 
specific aspects of immunotherapy.  
 
(2) Treatment studies of PDAC were performed with the 5’ppp-modified siRNA molecule ppp-Gal-1 
in the orthotopic Panc02 tumor model. The dual activities of this molecule were confirmed in vitro, 
leading to (i) reduced galectin-1 expression via RNAi; and (ii) production of CXCL10 and IFN-β, 
MHC-I up-regulation and apoptosis of tumor cells via RIG-I activation. Treatment of mice with 
orthotopic pancreatic tumors with ppp-Gal-1 significantly prolonged survival, as compared to 
unmodified OH-Gal-1 or control RNA. In addition, 20% of the mice completely rejected their tumors 
leading to long-term tumor control. Thus, bifunctional 5’ppp-modified siRNA is a promising treatment 
strategy for PDAC deserving further pre-clinical evaluation.  
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(3) Pancreatic tumor cells employ multiple mechanisms for suppression of T cell responses. This study 
identified TGF-β and IDO as two potent mechanisms leading to inhibition of T cell proliferation. 
Minute amounts of PDAC supernatants effectively blocked T cell proliferation induced by CD3 and 
CD28 triggering. This could be partially prevented by SD-208, a small molecule inhibitor of TGF-β 
receptor signaling, or by blocking IDO activity with D-1-MT. Interestingly, tumor supernatants 
induced up-regulation of IDO mRNA expression in T cells. Furthermore, blocking IDO activity in T 
cells appeared to be more effective than blocking IDO in tumor cells. This leads to a new hypothesis 
that factors secreted by the tumor cells induce IDO expression in T cells, which in turn leads to auto-
intoxication of the T cells via kynurenine production and eventually T cell apoptosis. Further studies 
confirming this hypothesis are warranted. 
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2 Introduction 
2.1 Biology and clinical aspects of pancreatic ductal adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDCA) is one of the most lethal solid malignancies and the fourth 
leading cause of cancer related deaths in North America (Howlader N, 1975-2010). PDAC accounts 
for the majority (>90%) of pancreatic malignancies (Cubilla and Fitzgerald, 1984). The incidence rate 
among men accounts for 13.9 and among women 10.9 per 100.000 persons (Howlader N, 1975-2010). 
Most patients are between 65 and 80 years old. Risk factors are smoking, diabetes mellitus, and 
chronic pancreatitis, e.g. due to alcohol abuse or a genetic predisposition (Schmiegel and Budach, 
2011). Pancreatic carcinoma has a high propensity for local invasion and distant metastases (Stathis 
and Moore, 2010). At the microscopic level, a dense and desmoplastic stroma surrounds the tumor, 
which is largely composed of fibrillar elements such as collagen I, fibroblastic and inflammatory cells 
(Chu et al., 2007, Mahadevan and Von Hoff, 2007). The interactions between the stroma and the 
cancer cells play critical roles in the process of tumor development and metastasis. Furthermore, the 
poorly vascularized stroma acts as a barrier for drug delivery in PDAC and contributes to the creation 
of a hypoxic microenvironment (Hidalgo and Von Hoff, 2012). 
 
The cancer originates in the ductal epithelium and evolves from premalignant lesions to dysplastic 
lesions and finally to fully invasive cancer. The initial lesion called pancreatic intraepithelial neoplasia 
(PanIN) is the best-characterized histologic precursor of pancreatic cancer (Hruban et al., 2008). 
PanINs can be divided into several stages. PanIN-1A reveals elongated cells with massive mucin 
production and PanIN-1B demonstrates a papillary architecture. PanINs of stage 2 depicts nuclear 
abnormalities, e.g. enlargement, some loss of polarity and crowding. Further, stage 3 shows budding 
into the lumen, severe nuclear atypia and abnormal mitosis events. These stages lead to 
adenocarcinoma with invasive growth and marked stromal reaction (desmoplasia) (Bardeesy and 
DePinho, 2002). Almost all patients with fully established pancreatic cancer carry one or more of four 
genetic defects (Maitra and Hruban, 2008). 90% of tumors have activating mutations in the Kirsten 
RAS (KRAS) oncogene. Transcription of the mutant KRAS gene produces an abnormal Ras protein 
that is “locked” in its activated form, resulting in aberrant activation of proliferative and survival 
signaling pathways. Likewise, 95% of tumors exhibit an inactivation of the CDNK2A gene, leading to 
the loss of the p16 protein and a corresponding increase in cell proliferation. Furthermore, the 
expression of TP53 is abnormal in 50 to 75% of tumors, permitting cells to bypass DNA damage 
control checkpoints and apoptotic signals and contributing to genomic instability. DPC4, also known 
as SMAD4, is lost in approximately 50% of pancreatic cancers, resulting in aberrant signaling by the 
transforming growth factor β (TGF-β) cell surface receptor (Hidalgo, 2010, Hidalgo and Von Hoff, 
2012, Iovanna et al., 2012). 
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The majorities of tumors develop in the head of the pancreas and cause obstructive cholestasis and 
jaundice (Hidalgo, 2010, Stathis and Moore, 2010). Many patients develop nonspecific nausea and 
abdominal or back pain. Other unspecific clinical signs are disglycemia or pancreatitis (Maitra and 
Hruban, 2008). Anorexia, weight loss, gastric outlet obstruction and ascites are usually manifestations 
of an advanced disease (Stathis and Moore, 2010). 
 
Therapy and prognosis of patients with PDAC depend on the extent of the disease at diagnosis. 
Surgical resection followed by an adjuvant therapy is the standard of care for patients diagnosed with 
early-stage disease. In most cases however, patients present with an advanced stage disease precluding 
surgical resection. In this situation the impact of standard chemotherapy is minimal (Stathis and 
Moore, 2010). Today’s standard first-line therapy for advanced stage disease is chemotherapy with the 
cytotoxic agent gemcitabine (Burris et al., 1997). Gemcitabine is a chemically analogue to the 
nucleoside cytidin. Upon uptake of gemcitabine during DNA replication the process is stopped and 
followed by apoptosis of the cell. Combination therapy of gemcitabine with erlotinib, which blocks 
EGF receptor signaling, showed some improvement in median survival of patients with metastatic 
disease, but only in patients with KRAS wild-type (Moore et al., 2007). In the last few years 
FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil and leucovorin) has emerged as the combination 
of choice for patients with excellent performance status. However, this aggressive therapy is 
accompanied by high toxicity (Conroy et al., 2011). FOLFIRINOX provided a median survival of 11.1 
months compared to 6.8 months in gemcitabine treated patients in a pivotal phase II/III trial (Conroy 
et al., 2011). Recently von Hoff et al. published a phase III trial evaluating weekly nab-paclitaxel 
(albumin-bound paclitaxel) plus gemcitabine versus gemcitabine alone (Von Hoff et al., 2013). Here 
they reported that the combination of nab-paclitaxel and gemcitabine prolongs the overall survival to 
8.5 months compared to 6.8 months for exclusively gemcitabine treated patients. This treatment 
appears to be less toxic than FOLFIRINOX and therefore patients with an excellent or average 
performance status can be treated (Von Hoff et al., 2013, Jarboe and Saif, 2013). 
2.2 Mouse models for pancreatic ductal adenocarcinoma 
In order to study the pathogenesis and novel therapies for PDAC mouse models mimicking the disease 
have been developed. These include subcutaneous or orthotopic implantation of murine pancreatic 
carcinoma cell lines in syngeneic, immunocompetent mice, xenografts of human cell lines in immune 
compromised mice and genetically engineered mouse models (GEMM), in which mutations that are 
commonly found in human cancers are introduced under the control of pancreas specific promotors 
(Herreros-Villanueva et al., 2012, Zhang et al., 2013). In this study two different murine cancer 
models for PDAC were employed: the chemically induced, widely used Panc02 model in which tumor 
cells are implanted in syngeneic C57BL/6 mice and GEMM, in which tumors express mutant p53 and 
Kras under the control of a pancreas-specific promotor, the so called KPC tumor model. 
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2.2.1 Chemically induced Panc02 tumor model 
Corbett et al. described in 1984 the establishment of the murine Panc02 tumor cell line (Corbett et al., 
1984). Briefly, cotton threads saturated with 3-methycholantren (3-MCA) were implanted in the 
pancreas of C57BL/6 mice. Tumors arising after 220 days post implantation displayed pancreatic 
ductal adenocarcinomas, whereas tumors with shorter latency (>220 days) usually represented 
fibrosarcomas. Panc02 were established in a serial passage in the host of origin (latency: 528 days) 
and originated as a grade II tumor, producing copious amounts of fluid and ulcerating through the skin 
after trocar implant at a very small size (< 400 mg). The tumor was characterized by a benign 
connective tissue component and was unsuitable for chemotherapy trials. With passage 26, a stable 
murine tumor cell line was established and transplantation back into mice showed that the tumor 
retained a well-differentiated histological appearance but produced very little fluid, did not ulcerate to 
the surface and contained no connective tissue elements. Panc02 tumors metastasized into the lung, 
lymph nodes and kidneys. Numerous groups have studied the Panc02 model since its first description 
in 1984 due to its easy handling, aggressive tumor growth characteristics and low sensitivity towards 
chemotherapy, which are typical features of the human disease.  
2.2.2 Genetically engineered mouse models 
In the last years numerous research groups have established GEMM by introducing specific mutations 
that had turned out to play a role in human disease to study PDAC carcinogenesis. These models 
reproduce genetic alterations implicated in the progression of pancreatic cancer, which includes 
activating Kras mutations and inactivation of tumor suppressor genes, such as p53, p16/INK4a, 
BRCA2 and Smad4 (Herreros-Villanueva et al., 2012). Since an activating mutation of Kras oncogene 
can be identified in up to 90% of all human pancreatic carcinomas, thus representing the most frequent 
genetic alteration, most of the GEMM are based on mutant Kras (Herreros-Villanueva et al., 2012).  
 
A mouse model targeting oncogenic Kras is the LSL-KrasG12D model. This model is generated by a 
conditionally expressed allele, using a vector containing genetic elements flanked by functional LoxP 
sites that inhibit transcription and translation. This Lox-Stop-Lox (LSL) construct was inserted into the 
mouse genomic Kras locus upstream of locus 1 comprising a G-A transition in codon 12 (G12D). This 
transition mutation results in a glycine to aspartic acid substitution in the expressed protein that 
activates constitutive downstream signaling of Ras effector pathways. Using the Cre-loxP-system, 
Cre-expression can be restricted to pancreatic cells by placing Cre under the PDX1 or Ptf1a (P48) 
promoter. The transcription factors PDX-1 and P48 play important roles in the embryonic 
development of the pancreas. For the generation of Ptf1a(P48)-Cre, LSL-KrasG12D mice, a mouse 
model, which expresses a Cre-activated KrasG12D allele inserted into the endogenous Kras locus, was 
crossed with mice expressing Cre recombinase under the tissue specific promoter Ptf1a(P48) 
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(Hingorani et al., 2003). These mice express numerous PanIN lesions, but showed low frequency of 
progression to invasive and metastatic adenocarcinoma (Herreros-Villanueva et al., 2012). 
 
Another transgenic mouse model, PDX-1-Cre, LSL-KrasG12D, LSL-Trp53R172H/-, was generated by 
Hingorani et al. (Hingorani et al., 2005). They generated a conditionally expressed point mutant allele 
of the Li-Fraumeni human ortholog, TRP53R172H. Activation of both the KrasG12D and the Trp53R172H 
alleles occurs in tissue progenitor cells of the developing mouse pancreas through interbreeding with 
PDX-1-Cre transgenic animals (KPC mice) (Hingorani et al., 2005). KPC mice develop early PanIN 
lesions and later invasive lesions whereby histological analysis showed a well-differentiated 
morphology as in human PDAC. Cytokeratin 19 (CK 19) expression shows ductal phenotype and the 
carcinomas contain frequently mucin as revealed by Alcian blue staining (Hingorani et al., 2005). 
KPC mice develop liver and lung metastasis and the median survival decreased from 12 month of 
PDX-1-Cre, LSL-KrasG12D mice to 5 month. Clinical features of the triple mutant mice are cachexia, 
abdominal distension and hemorrhagic ascites (Hingorani et al., 2005). 
 
Besides the described GEMM, there are further models resulting in PDAC, which are summarized in 
Table 2-1. The cell line T110299, which was used in this study, was developed from a primary tumor 
of a KPC mouse in the Jens Siveke lab (TU Munich). 
 
Table 2-1: GEMMs of pancreatic ductal adenocarcinoma (modified from Mazur et al.(Mazur and Siveke, 
2011)) 
genotype Preneoplastic lesion 
Onset 
(months) 
Median 
survival 
(months) 
comments 
Pdx1-Cre;KrasG12D + >12 >12 Long latency, PanINs 
Ptf1a+/Cre;KrasG12D + >12 >12 Long latency, PanINs 
Ela-Tgfa + --- >12 Development of ADM and fibrosis 
Ptf1a+/Cre;KrasG12D; 
Ela-Tfga + 5 7 PanIN and IPMN-derived PDAC 
Pdx1-Cre;KrasG12D; 
INK4a/ARFlox/lox + 2 2 Short latency, high penetrance 
Pdx1-Cre;KrasG12D; 
INK4a/ARF+/- + 8 10 Gross metastasis 
Pdx1-Cre;KrasG12D; 
INK4a-/- +  5 PDAC with short latency 
Pdx1-Cre;KrasG12D; 
p53lox/lox + 1.5 3 
Well-differentiated PDAC, with short 
latency 
Pdx1-Cre;KrasG12D; 
p53R172H/+ + 2.5 5 
Accelerated development of 
metastatic well-diff. PDAC 
Ptf1a+/Cre;KrasG12D; 
Notch1lox/lox + >6 12 Similar to Ptfa
+/Cre;KrasG12D 
Ptf1a+/Cre;KrasG12D; 
Notch2lox/lox + >9 >15 
MCNs, only PanIN1, sarcomatoid 
PDAC with long latency 
Pdx1-Cre;KrasG12D; 
Smad4lox/lox + 4 9 
Model of IPMN-to-PDAC 
progression 
Ptf1a+/Cre;KrasG12D; + 3.5 8 MCNs resembling human disease 
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Smad4lox/lox 
Ptf1a+/Cre;KrasG12D; 
p53R270H/+;Brca2Tr/D11 + 2 2.5 Model of familial PDAC 
Ela-tTA TRE-Cre; 
KrasG12V + 12 18 PDAC after chronic pancreatitis 
Ptf1a+/Cre;KrasG12D; 
TFGβIIRlox/lox +  2 Aggressive, undifferentiated PDAC 
Ela-CreERT; 
KrasG12D +  >18 Acinar-derived PanINs 
ADM=acinar-ductal metaplasia; IPMN=intraductal papillary mucinous neoplasm; MCN=mucinous cystic 
neoplasm; PanIN=pancreatic intraepithelial neoplasia; PDAC=pancreatic ductal adenocarcinoma; + = yes 
2.3 Tumor immunology and immunotherapy 
Tumor immunology studies the interactions of cancer cells with immune cells. Immunotherapy aims at 
exploiting immune effector mechanisms to specifically target and to eradicate tumor cells. The 
concept of immune surveillance by Burnet et al. states that a physiologic function of the immune 
system is to recognize and destroy clones of transformed cells before they grow into tumors and to kill 
these cells after they are formed (Burnet, 1970, Abbas et al., 2007). However, some clones may 
survive the immune attack and after an equilibrium period, in which tumors are usually small, tumor 
cells evolve mechanisms to escape immunosurveillance leading to clinical apparent tumor outgrowth 
(Hanahan and Weinberg, 2000, Zitvogel et al., 2006). A major challenge for future immunotherapies 
will be to identify and overcome these immunosuppressive mechanisms (Clark et al., 2009). In the 
following paragraphs important components of the immune system in regard to tumor immunotherapy 
will be discussed. 
2.3.1 The innate and adaptive immune system 
The immune system is divided in two major divisions, the innate or non-specific immune system and 
the adaptive or specific immune system. The innate immune system represents the first line of defense 
against invading pathogens whereas the adaptive immune system acts as a second line of defense and 
enables protection against re-exposure to the same pathogen (Abbas et al., 2007). 
 
The mechanisms of innate immunity provide the initial defense against infections, which are triggered 
by phagocytes (macrophages, neutrophils), dendritic cells (DCs), mast cells and natural killer (NK) 
cells. These cells use non-clonal recognition receptors, including membrane-bound Toll-like receptors 
(TLRs), NOD-like receptors (NLRs) and cytosolic helicases (Palucka and Banchereau, 2012). The 
innate immune system can also be considered to be a property of the skin and epithelia that line our 
internal organs, such as the gut and lungs, providing a first line defense against invading pathogens 
(Janeway and Medzhitov, 2002). Innate immunity is antigen-nonspecific (Palucka and Banchereau, 
2012). 
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The adaptive immune system can specifically recognize proteins, carbohydrates, lipids and nucleic 
acids (antigen-specific). The adaptive immune response develops later as the innate response and 
consists mainly of the activation of T and B cells. T and B cells have clonal receptors allowing 
enormous variability in immune recognition (Palucka and Banchereau, 2012). The adaptive immune 
system is separated into humoral and cell-mediated immune responses. In humoral immunity, B cells 
secrete antibodies that prevent infections and eliminate extracellular microbes. In cell-mediated 
immunity, T helper cells activate macrophages to kill phagocytosed microbes or cytotoxic T cells 
directly destroy infected cells (Abbas et al., 2007, Janeway and Medzhitov, 2002, Palucka and 
Banchereau, 2012).  
 
Dendritic cells of the innate immune system express co-stimulatory molecules, such as CD80 and 
CD86 on the cell surface, to instruct the adaptive immune system about the nature of the pathogenic 
challenge. The virtue of having both innate and adaptive systems of recognition is that the interplay of 
these two distinct systems allows the discrimination of an infectious attack on the host from 
noninfectious self (Janeway and Medzhitov, 2002).  
In the following sections DCs and T cells are explained in more detail. 
2.3.1.1 Dendritic cells 
DCs are rare cell types and key cellular sensors of microbes. They provide an essential link between 
innate and adaptive immune responses and the generation of protective anti-tumor immunity depends 
on the presentation of tumor antigens by DCs (Diamond et al., 2011, Fuertes et al., 2011, Palucka and 
Banchereau, 2012). DCs are specialized for the capture, processing and presentation of antigens to T 
cells. There are differences in the maturity and the function of DCs during their life cycle. DCs located 
in peripheral tissues are immature and induce T cell tolerance by presenting self-antigens to T cells, 
which leads to T cell deletion or expansion of regulatory T cells (Tregs) (Palucka and Banchereau, 
2012). By contrast, mature, antigen-loaded DCs can mediate the differentiation of antigen-specific T 
cells into effector cells. 
 
DCs can be divided into different subtypes. The subtypes differ in location, migratory pathways, 
immunological function and dependence on infections or inflammatory stimuli for their activation 
(Palucka and Banchereau, 2012). There are conventional DCs (cDCs) and plasmacytoid DCs (pDCs), 
also known for their function to secrete high levels of type I interferons. Subtypes of cDCs are 
migratory DCs and lymphoid-tissue-resident DCs (Palucka and Banchereau, 2012, Shortman and 
Naik, 2007). Migratory DCs act as sentinels in the peripheral tissue. They are activated by pathogen-
associated molecular patterns (PAMPS), e.g. via Toll-like receptors (TLRs), migrate to the draining 
lymph nodes, and present endocytosed antigen as processed peptides on major histocompatibility 
complex (MHC) class I or II molecules to T cells (Shortman and Naik, 2007, Palucka and Banchereau, 
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2012). Lymphoid-tissue-resident DCs collect and present foreign and self-antigens and can be further 
subdivided into CD4+ and CD8+ and double-negative cDCs (Shortman and Naik, 2007). 
 
Mouse bone marrow cells cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) 
and other cytokines (like IL-4) produce mixtures of granulocytes, macrophages, and monocyte-derived 
DCs, expressing high levels of CD11c and MHC class II and thereby acting as potent antigen-
presenting cells (APC) (Liu and Nussenzweig, 2010, Sallusto and Lanzavecchia, 1994). These 
“model” DCs are frequently used for in vitro studies of antigen presenting cell (APC) functions. 
2.3.1.2 T lymphocytes 
T cells are the mediators of cellular immunity and consist of three major subsets, CD4+ helper T 
lymphocytes (TH), CD8+ cytotoxic T lymphocytes (CTL) and regulatory T lymphocytes (Tregs) which 
all express the αβ-antigen receptor (Andersen et al., 2006). 
 
CD4+ T cells recognize peptides presented onto MHC class II on APCs and can only be activated with 
appropriate co-stimulatory molecules on the surface of professional APCs, such as DCs (Andersen et 
al., 2006, Stockwin et al., 2000). The effector functions of CD4+ T cells are triggering the humoral and 
cell-mediated immune response by activation of macrophages and B cells. 
 
CD8+ T cells recognize specific peptide epitopes presented on MHC class I molecules, which are 
expressed by virtually all cells and present endogenous peptides generated by the proteasome 
(Andersen et al., 2006). In addition CD8+ T cells can be activated by DCs via cross-presentation of 
extracellular peptides which were phagocytosed and processed by DCs and finally presented on MHC 
class I molecules (Zhang and Bevan, 2011, Andersen et al., 2006). CD8+ T cells have three possible 
ways of killing a target cell. Firstly, the release of lytic molecules, such as perforin and granzymes, 
into the intercellular space. Secondly, CTLs express Fas ligand (CD95L) on their surface which binds 
to Fas receptor (CD95) on the target cell, triggering apoptosis through the classical caspase cascade 
(Nagata, 1996). The third possibility does not require cell-cell contact but can reach target cells distal 
to T effector cells by secreting cytokines, such as IFN-γ and TNF-α. TNF-α induces its receptor on the 
target cell and mediates the caspase cascade leading to apoptosis of the target cell. IFN-γ induces up-
regulation of MHC class I molecules and increases Fas mediated cell lysis (Andersen et al., 2006). 
CTLs can provide protection against malignant cells by their ability to detect antigenic differences in 
transformed cells due to their altered protein repertoire (Andersen et al., 2006). 
2.3.1.3 Co-signaling interactions in T cells 
For full activation of T cells, co-stimulatory molecules are required, which deliver positive signals to 
T cells following their engagement by ligands and counter-receptors on APCs. Binding of CD28 on T 
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cells to B7-1 (CD80) and B7-2 (CD86) on APCs or CD40 on T cells to CD40L on APCs stimulate 
proliferation, cytokine production, differentiation, cytotoxic function, memory formation and survival 
(Chen and Flies, 2013). 
 
In contrast, co-inhibitory molecules deliver negative signals to T cells. For example, CTLA-4 on T 
cells is induced after T cell activation and binds to B7-1 and B7-2 in competition to CD28. This 
binding induces expression of Indoleamine 2,3-dioxygenase (IDO) in APCs, which acts in trans to 
suppress activation of conventional T cells and promote the function of Tregs. In addition, B7-H1, also 
known as programmed death-ligand 1 (PD-L1), is expressed on APCs and binds to the PD-1 receptor 
on T cells, thereby inducing cell cycle inhibition, inhibition of effector functions, T cell anergy and 
apoptosis (Chen and Flies, 2013). 
2.3.1.4 Interaction of T lymphocytes with dendritic cells 
DCs are the most effective APCs for initiating primary T cell response. DCs are strategically located 
at common entry sites of microbes and they are enabled to capture and respond to them via specific 
receptors. DCs migrate preferentially to the T cell zone of lymph nodes and mature DCs up-regulate 
co-stimulatory molecules (CD80 and CD86) and secrete IL-12 to activate T cells (Abbas et al., 2007). 
The T cell receptors of CD4+ or CD8+ T cells recognize peptides loaded onto MHC class I or II 
molecules on DCs, leading to the formation of the immunological synapse or supramolecular 
activation cluster (SMAC). While naïve CD4+ T cells can differentiate into T helper cells (TH1, 2 and 
17) as well as Tregs, naïve CD8+ T cells can give rise to effector cytotoxic T lymphocytes (CTLs) 
(Palucka and Banchereau, 2012). Both T cell types produce IL-2 after their activation to stimulate T 
cell proliferation in an autocrine and paracrine manner. 
2.3.2 Role of T cells in pancreatic cancer 
Tumors with reduced immunogenicity or those that have acquired mechanisms to suppress immune 
effector functions can emerge from cancer immunosurveillance and grow progressively. This is an 
important issue in pancreatic cancer (Clark et al., 2009). Studies in mouse models of PDAC give rise 
to the assumption that immune cells with suppressive properties infiltrate the pancreas early during 
tumorigenesis, preceding and undermining any lymphocytes with potential antitumor function (Clark 
et al., 2007). Therefore, the failure of cancer immunosurveillance is likely to be an early event in 
PDAC. 
 
In the development from PanINs to invasive cancer, a massive infiltration with CD45+ leukocytes can 
be observed. In early stages immunosuppressive leukocytes, such as tumor-associated macrophages 
(TAM), myeloid-derived suppressor cells (MDSC) and Tregs enter the tumor stroma accompanied by 
progressive tumor growth (Clark et al., 2009, Clark et al., 2007, Vonderheide and Bayne, 2013). 
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Effector T cells are rare in preinvasive and invasive lesions and most T cells show a naïve phenotype 
without evidence of activation. Some tumor-specific T cells have been noted but these were typically 
dysfunctional (Garbe et al., 2006, Mukherjee et al., 2001). Vonderheide et al. proposed a hypothesis 
for T cell evasion in PDAC (Vonderheide and Bayne, 2013, Clark et al., 2009). They propose a 
dynamic model of the “four I” hypothesis: induction, inflammation, immune suppression and immune 
privilege. Induction – through alterations in oncogenes and tumor-suppressor genes like Kras and p53. 
Inflammation – through soluble factors secreted by PanIN lesions that facilitate a local inflammatory 
reaction composed of stromal and immune cells. Immune suppression – via infiltrating suppressive 
immune cells (TAMs, MDSCs, Tregs) inhibiting the development of an adaptive immune response 
through both the secretion of immunosuppressive cytokines, such as TGF-β, IL-10 and GM-CSF 
(Bayne et al., 2012, Pylayeva-Gupta et al., 2012), and direct cell-cell contact. And last but not least, 
immune privilege – with progression to PDAC, as neoplastic lesions maintain the capacity for immune 
evasion through both tumor- and immune-mediated mechanisms of suppression thereby establishing a 
site of immune privilege (Clark et al., 2009). 
2.3.3 Immunotherapy of pancreatic cancer 
Pancreatic cancer is mostly diagnosed in an advanced stage. Therefore, surgical resection can be 
performed in only a small number of patients and even after resection, recurrence occurs in the 
majority of the patients. Although adjuvant treatment with both chemotherapy and radiation therapy 
was demonstrated to induce some improvements in disease-free and overall survival rates, new 
therapeutic approaches are still urgently needed (Koido et al., 2011). 
 
The aim of cancer immunotherapy is to activate the immune system for therapeutic benefit. Therefore, 
the cancer-immunity cycle has to be initiated or reinitiated (Chen and Mellman, 2013, Mellman et al., 
2011). This cycle includes seven steps: (1) the release of tumor antigens through immunogenic cancer 
cell death. (2) the presentation of tumor antigens by DCs on MHC class I or II molecules to T cells in 
the lymph node, leading to (3) the priming and activation of these T cells. Afterwards, effector T cells 
traffic to the tumor site (4) and infiltrate the tumor (5). CTLs specifically recognize and bind to cancer 
cells (6) to kill their targets (7), leading to the release of new tumor antigens (back to step 1) (Chen 
and Mellman, 2013). Though, in most cancer patients this cancer-immunity cycle does not perform 
faultless. 
 
For immunotherapy of PDAC different strategies have been developed to activate the immune system, 
including therapeutic vaccines using tumor associated antigens (TAAs) and adoptive T cell transfer. 
For the traditional therapeutic vaccination whole cancer vaccines or established cell lines as crude 
vaccines have been used (Gaudernack, 2006). The advantages that accrued from this approach are that 
(1) no specific tumor antigen needs to be identified, (2) immune responses to multiple tumor antigens 
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can be generated, and (3) such vaccines are not limited by patient HLA haplotype (Dodson et al., 
2011). A further refinement of this approach is to increase the immunogenicity of such vaccines by 
genetically introducing immune stimulating genes, such as GM-CSF gene (Jaffee et al., 1998).  
 
Another approach has been the characterization of TAAs. The idea is based on the assumption that 
molecules associated with pancreatic cancer and that have been used for diagnostic purposes could 
also be utilized for therapeutic vaccines (Gaudernack, 2006). To date there are several TAAs that have 
been identified in pancreatic cancer, such as Wilms’ tumor gene 1 (WT1), mucin 1 (MUC1), mutated 
Kras, carcinoembryonic antigen (CEA), human telomerase reverse transcriptase (hTERT), survivin, 
HER2/neu, and p53 or mesothelin (Koido et al., 2011, Dodson et al., 2011). However, there has been 
the problem that the immune system has already generated tolerance towards them. Furthermore, most 
of the TAAs are not exclusively restricted to malignant tissue (Gaudernack, 2006).  
 
Another promising alternative with respect to a vaccination therapy is the design of DC-based cancer 
vaccines (Koido et al., 2011). DCs can be pulsed with synthetic peptides derived from known tumor 
antigens, tumor cell lysates or apoptotic tumor cells (Koido et al., 2011). Besides, DCs can be 
transfected with whole tumor cell DNA or RNA, or fused to tumor cells to induce antigen-specific 
polyclonal CTL responses (Koido et al., 2011). An alternative strategy is to target DC directly in vivo 
using tumor antigens formulated with adjuvants, such as DEC205 mAb (Bonifaz et al., 2004) or 
ISCOMATRIX adjuvant (Jacobs et al., 2011, Davis et al., 2004). 
 
The adoptive T cell transfer technology includes the selective expansion of the patient’s own T cells 
directed against a specific antigen followed by reinfusion into the patient (Dodson et al., 2011). 
Moreover, much effort is spent on the development of chimeric antigen receptors (CARs), these are 
engineered receptors grafting the specificity of a monoclonal antibody onto a T cell. For this purpose, 
the T cells of patients are transfected with a construct encoding an antibody against a tumor surface 
antigen fused to T cell signaling domains (Chen and Mellman, 2013). The resulting T cells recognize 
the tumor antigen in its native form and do not rely on presentation of antigens by MHC molecules 
(Dodson et al., 2011). 
2.4 Mechanisms of immune suppression in pancreatic cancer biology 
The microenvironment in PDAC as well as the cancer cells themselves contribute to the 
immunosuppressive milieu found in the tumors. A multitude of cellular and molecular aspects have to 
be considered. 
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2.4.1 Cellular aspects 
Different cell types are responsible for tumor immune evasion, including tumor-associated 
macrophages (TAMs), myeloid derived suppressor cells (MDSCs), regulatory T cells (Tregs), and 
tolerogenic dendritic cells (DCs). Another important aspect with regard to immune suppression is the 
tumor microenvironment including stromal cells. 
2.4.1.1 Tumor-associated macrophages 
The most abundant leukocyte subset in PDAC is represented by TAMs, that can be identified by 
CD11b+ expression, which cluster around neoplastic ducts starting in very early stages (Clark et al., 
2009). TAMs can be divided into two different populations, the classical/M1-activated macrophages 
(CD68+) and the alternative/M2-activated macrophages (CD163+). The M1-activated macrophages act 
against intracellular pathogens as well as tumor cells, providing an anti-tumorigenic response by 
secreting IFN-γ (Ruffell et al., 2012, Wormann et al., 2013). The M2-activated macrophages initiate a 
pro-tumorigenic response by promoting angiogenesis and invasion (Wormann et al., 2013, Ruffell et 
al., 2012). Furthermore, TAMs can inhibit anti-tumor T cell responses by production of Indoleamine 
2,3-dioxygenase metabolites and reactive oxygen species (Pollard, 2004, Bronte et al., 2003). 
2.4.1.2 Myeloid-derived suppressor cells 
Other immunosuppressive myeloid cell types are MDSCs, representing prominent populations in 
tumors as well as in spleens of tumor-bearing hosts. MDSCs are characterized by CD11b and Gr-1 
expression on their surface and are recruited to tumors by GM-CSF, which is secreted by tumor cells 
(Bayne et al., 2012). Two major subtypes can be discriminated in mice, Ly6G+ granulocytic MDSCs 
and Ly6C+ monocytic MDSCs (Gabrilovich et al., 2012). MDSCs are able to impair T effector T cell 
functions in a number of ways. They can inhibit antigen-specific responses (proliferation, cytokine 
production and cytotoxicity) mediated by T cells (Clark et al., 2009, Gabrilovich et al., 2001). 
Furthermore, they can cause down-regulation of the T cell ζ chain, a key component in TCR signaling. 
Last but not least, they can induce the development of Tregs and have the capacity to induce T cell 
apoptosis (Clark et al., 2009). Within the tumor microenvironment the predominance of MDSCs 
inversely correlates with that of CTLs in the leukocytic infiltrate of pancreatic tumors, raising the 
possibility that MDSCs may negatively affect T cell trafficking or T cell survival within PDAC (Clark 
et al., 2009, Clark et al., 2007). 
2.4.1.3 Dendritic cells 
Tumor cells have the capability to establish an immunosuppressive environment by inhibiting 
maturation and function of DCs (Wormann et al., 2013, Pinzon-Charry et al., 2005). Differentiation 
and antigen presentation of DCs can be suppressed by PDAC conditioned medium in vitro (Wormann 
et al., 2013, Bharadwaj et al., 2007). But additionally DCs and macrophages produce 
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immunosuppressive enzymes, such as IDO and COX2, and secrete immune modulatory and 
chemotactic factors, such as IL-6, TGF-β, CCL2 and CCL20 (Wormann et al., 2013). Therefore, DCs 
may also exhibit tumor-promoting functions including active suppression of cytotoxic T cell functions 
by TGF-β-dependent Treg proliferation and l-arginine metabolism (Wormann et al., 2013). Besides, 
DCs may have impaired antigen presenting function and diminished capacity to induce tumor-specific 
T cell activation (Wormann et al., 2013).  
2.4.1.4 Regulatory T cells 
Infiltration of Tregs in preinvasive lesions is an early event during PDAC development (Liyanage et 
al., 2002), possibly mediated by tumor-derived TGF-β and CCL5, which converts CD4+ T cells into 
Tregs (Moo-Young et al., 2009). Their presence within tumors has been linked with decreased 
survival (Curiel et al., 2004). Tumor-associated Tregs can inhibit T cell production of IFN-γ and IL-2 
in response to tumor-associated antigens, as well as their cytotoxic functions. In PDAC, Tregs control 
the anti-tumor response from PanINs to invasive cancer and are markers of poor prognosis (Hiraoka et 
al., 2006). 
2.4.1.5 Tumor microenvironment 
A prominent feature of pancreatic cancer is the presence of an abundant tumor stroma accounting for 
up to 90% of the tumor mass (Neesse et al., 2011). Tumor stroma as a physical barrier can be one 
factor contributing to the failure of systemic therapies (Feig et al., 2012). Pancreatic tumor stroma is 
very heterogeneous, comprising fibroblasts, myofibroblasts, pancreatic stellate cells (PSCs), immune 
cells, blood vessels, extracellular matrix (ECM) and soluble proteins, such as cytokines and growth 
factors. The tumor microenvironment is not a static entity but dynamic in its composition, especially 
in the progression from preinvasive to invasive lesions (Feig et al., 2012).  
 
ECM components include collagen, fibronectin, proteoglycans and hyaluronic acid and the 
composition is regulated by matrix metalloproteinases (MMPs). MMP-2 and MMP-9 are 
overexpressed in PDAC and play an important role in tumor cell migration and invasion by degrading 
the surrounding ECM (Neesse et al., 2011, Ellenrieder et al., 2000). The immunosuppressive actions 
of MMPs are cleaving growth factors and cytokine receptors, e.g. the IL-2 receptor (IL-2α), thereby 
inhibiting proliferation and activation of T cells (Becker et al., 2013). MMPs also increase the 
bioavailability of TGF-β by regulating the release from an inactive extracellular complex (Becker et 
al., 2013). 
 
PSCs are an important regulator of desmoplasia in PDAC and are normally located in the space 
between acini and endothelial cells. Stellate cells can be found in two stages, a quiescent form under 
physiological conditions and an activated form under acute and chronic inflammatory conditions. 
Introduction 
15 
Pancreatic cancer cells induce PSC activation in vitro by growth factors such as TGF-β1, PDGF and 
VEGF. In the activated stage PSCs undergo morphological changes and express α-smooth muscle 
actin (α-SMA). They secrete high amounts of collagen I and III, fibronectin and MMPs, leading to the 
deposition of ECM (Neesse et al., 2011, Omary et al., 2007, Apte et al., 1998). Xue et al. identified 
PSCs as the primary source of galectin-1 in PDAC stroma where it promotes proliferation and 
invasion of pancreatic cancer cells (Xue et al., 2011). At the same time, Tang et al. demonstrated that 
galectin-1 secreted by PSCs plays a role in the development and maintenance of an 
immunosuppressive microenvironment in PDAC by inducing apoptosis of CD4+ and CD8+ T cells 
(Tang et al., 2011). 
2.4.2 Molecular mechanisms 
2.4.2.1 Galectin-1 
It is known that pancreatic carcinoma cells produce a variety of immunosuppressive proteins. One of 
these is galectin-1. Dimeric galectin-1 secreted by tumor cells contributes to tumor immune escape by 
inducing apoptosis in effector T cells, especially T helper cells 1 (TH1) and TH17 cells, but not in 
naïve, TH2 or regulatory FoxP3+ T cells (Treg). This is caused by the glycosylation on these cells that 
prevents binding to galectin-1. Galectin-1 secretion leads to the expansion of regulatory T cells, 
promotes angiogenesis and inhibits transendothelial migration of effector T cells into the tumor (Yang 
et al., 2008, Cedeno-Laurent and Dimitroff, 2011, Toscano et al., 2007). In addition, galectin-1 
changes the cytokine balance towards a TH2 type, characterized by increased IL-4 and IL-5 levels, 
whereas the levels of IFN-γ, IL-2 and IL-17 decreases. Cedeno-Laurent et al. showed that both 
uncommitted and polarized TH cells exposed to galectin-1 express an immune regulatory signature 
defined by IL-10 production (Cedeno-Laurent et al., 2012). Tumor cells secreting galectin-1 use this 
strategy to promote tumor growth and to escape from the immune system. It is of importance, that 
killing of T cells by Galectin-1 secreting tumor cells depends on the expression and cell surface 
presentation of galectin-1 by the tumor cells and requires intimate cell-cell contact between the target 
and effector cells (Kovacs-Solyom et al., 2010). 
2.4.2.2 Transforming growth factor beta (TGF-β) 
TGF-β is a member of a superfamily of growth factors and consists of five isoforms of which type 1 to 
3 are found in mammals (de Visser and Kast, 1999). TGF- β1 circulates in the blood and is the most 
rapidly induced factor. TGF-β mediates protection against immune attack in the tumor (Rubtsov and 
Rudensky, 2007). In the presence of TGF-β1 and IL-2 naïve CD4+ T cells differentiate into FoxP3+ 
Treg cells, which themselves secrete TGF-β in an auto- and paracrine manner, thereby suppressing 
effector T cells (Rubtsov and Rudensky, 2007). TGF-β is produced by a variety of cells, including 
platelets and osteoblasts but also lymphocytes, macrophages and neutrophils secrete TGF-β under 
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certain conditions (de Visser and Kast, 1999). Furthermore, tumor cells are also known to express 
TGF-β (de Visser and Kast, 1999). The production of TGF-β can be advantageous for tumor growth 
due to the suppression of immunosurveillance. Other mechanisms include the promotion of 
angiogenesis, metastasis and connective tissue formation (de Visser and Kast, 1999). In addition, 
TGF- β has inhibitory effects on CTLs, i.e. it suppresses the expression of pore-forming protein (PFP), 
a crucial molecule in the cytolytic pathway. Inhibition of cytokine production in CTLs, like IFN-γ and 
TNF-α, as well as down-regulation of IL-2R inhibits T cell proliferation (de Visser and Kast, 1999). 
Another mechanism of TGF-β-induced suppression of T cell expansion in response to antigen and IL-
2 is the induction of apoptosis (Weller et al., 1994). We have shown in vitro and in vivo that TGF-β is 
highly abundant in tumor-conditioned medium of Panc02 tumor cells and in serum of Panc02-tumor-
bearing mice, respectively (Ellermeier et al., 2013). 
2.4.2.3 Indoleamine 2,3-dioxygenase (IDO) 
IDO catalyzes the first and rate limiting step of the oxidative catabolism of tryptophan to kynurenine, 
the first step in the biosynthesis of the central metabolic regulator nicotinamide adenine dinucleotide 
(NAD) (Prendergast, 2008, Johnson et al., 2009). Functional IDO activity depends on the binding of 
IDO to heme, on a substrate supply, redox potentials and the absence of heme toxins, such as nitric 
oxide (Johnson et al., 2009). There are two closely linked, homologous genes (IDO1 and IDO2) 
located in syntenic regions of chromosome 8 in humans and mice encoding IDO proteins (Ball et al., 
2007, Johnson et al., 2009). The genes possess one or more IFN response elements in their promoter 
regions, thus IFNs are potent inducers of IDO in several cell types, including DCs, macrophages, 
eosinophils, epithelial and endothelial cells (Johnson et al., 2009).  
 
In DCs, IDO expression can be induced by binding of CTLA-4 to B7 molecules (Fallarino et al., 2003, 
Muller and Prendergast, 2007). In tumors, IDO+ pDCs are present protecting the tumor from 
immunosurveillance by regulating local T cell responses that could otherwise eliminate premalignant 
cells (Johnson et al., 2009). The tryptophan metabolites cause cell cycle arrest, apoptosis and anergy in 
T cells, meaning that IDO activity blocks both clonal expansion of CD8+ and CD4+ T cells and 
generation of CTLs and TH cells while having less impact on TH2 cells (Fallarino et al., 2002). In 
contrast, IDO activity in pDCs promotes de novo Treg differentiation from naïve CD4+ precursors 
(Fallarino et al., 2003). But how does IDO block T cell responses? Activated T cells secrete INF-γ, 
which results in the up-regulation of IDO in APCs, suggesting a negative feedback loop to regulate T 
cell activation (Grohmann et al., 2003, Katz et al., 2008). Moreover, the secretion of IFN-γ induces T 
cells to undergo IDO-mediated apoptosis by activation of the caspase pathway and tryptophan 
deprivation causes enhanced Fas-dependent apoptosis and growth arrest of activated T cells (Lee et al., 
2002, Johnson et al., 2009, Katz et al., 2008). Additionally, T cells respond to tryptophan starvation by 
inducing the stress-signaling pathway via GCN2 that alters eIF2α phosphorylation and translational 
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initiation at the ribosome leading to cell growth arrest (Munn et al., 2005). The combined effects of 
tryptophan starvation and tryptophan catabolites act via the aryl hydrocarbon receptor (AHR) of T 
cells (Fallarino et al., 2012). Indirectly, IDO induced Tregs mediate suppression of effector T cells via 
a unique and distinctive mechanism dependent on intact PD-1/PD-L1 signaling (Johnson et al., 2009, 
Sharma et al., 2007). Witkiewicz et al. found that IDO is expressed in the cytoplasm of well-
differentiated pancreatic adenocarcinomas, in lymph node metastasis and in human pancreatic cancer 
cell lines but it is not expressed in healthy pancreatic tissue (Witkiewicz et al., 2008). They could also 
show that Tregs were increased in IDO expressing tumors. In addition, IDO2 is overexpressed in 
PDAC and may represent an attractive target in pancreatic cancer (Witkiewicz et al., 2009). Recently, 
it has been reported that the aggressiveness of intraductal papillary mucinous neoplasms (IPMN), 
another kind of precursor lesion of pancreatic cancer, significantly correlated with the number of Tregs 
and IDO-expressing cells in pancreatic tissue (Ikemoto et al., 2013). In Figure 2-1 the effects of IDO-
expressing tumors are summarized. 
 
Figure 2-1: Effects of IDO-positive tumors (modified from Godin-Ethier et al.) 
The different aspects are divided based on their impact on the immune system, tumor progression or tumor 
regression (Godin-Ethier et al., 2011). 
2.5 Therapeutic application of RNA interference 
In this study, a novel therapeutic strategy involving RNA interference (RNAi) was used to counteract 
immunosuppressive mechanisms mediated by galectin-1 in tumor-bearing mice. In addition, the 
immune activating properties of 5’ppp-modified siRNA were assessed for the treatment of murine 
PDAC by generating a bifunctional siRNA that combines galectin-1 gene silencing with RIG-I-
mediated immune activation in one molecule. 
2.5.1 RNA interference 
The RNAi machinery, which is found in all cells, can be harnessed to silence gene expression with a 
high degree of specificity. When synthetic, short double-stranded RNAs, called small interfering 
RNAs (siRNA) that resemble sequences of the mRNA are introduced to the cytoplasm of cells, the 
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double strand is split up into the passenger (sense) and the guide (antisense) strand. While the 
passenger strand is degraded, the guide strand is incorporated into the RNA-induced silencing 
complex (RISC) and can guide the cleavage of mRNAs bearing an exactly complementary sequence 
(Elbashir et al., 2001, Petrocca and Lieberman, 2011). This cleavage is performed by argonaute or 
Ago protein which is a RISC ribonuclease enzyme (Ambros, 2004). In case of a partial 
complementarity between the mRNA and the siRNA, the mRNA is not degraded, however the 
translation is interrupted (Petrocca and Lieberman, 2011). siRNAs can be designed to silence any gene 
of interest. In cancer, RNAi can be used to suppress for example oncogenic transcription factors or 
other regulating proteins (Petrocca and Lieberman, 2011). It is relatively simple to develop a new 
candidate siRNA once a target has been identified. Another advantage of siRNAs is that they are 
active at low concentrations (Petrocca and Lieberman, 2011). However, a negative aspect of this gene 
silencing technique is that the effect is temporally limited as the RISC with the incorporated siRNA 
gets divided between daughter cells. Therefore, in fast proliferating tumor cells, gene silencing lasts 
for less than a week (Petrocca and Lieberman, 2011). Furthermore, there are off-target effects of 
RNAi, including that the siRNA is recognized by immune sensors of viral infection, such as TLRs in 
the endosomes or RIG-I like helicases in the cytoplasm (Hornung et al., 2005). These off-target effects 
can be deliberately exploited using the 5’ppp-modified siRNA technology. 
2.5.2 5’ppp-modified siRNA 
A distinct and independent biological property of RNA oligonucleotides is their ability to activate 
immunoreceptors specialized for the detection of viral nucleic acids (Poeck et al., 2008). One 
cytoplasmic sensor for viral RNA is the RIG-I helicase retinoic-acid inducible gene-I (RIG-I) 
(Yoneyama et al., 2004). RIG-I detects RNA with a triphosphate (ppp) group at the 5’ end (Hornung et 
al., 2006, Pichlmair et al., 2006). Detection of ppp-siRNA by RIG-I leads to the induction of type I 
interferons (IFN) as well as the secretion of pro-inflammatory cytokines and chemokines via 
recruitment of the adapter molecule Interferon-β promoter stimulator 1(IPS-1) and phosphorylation of 
the transcription factor IFN regulatory factor 3 (IRF-3) and IRF-7 (Cao, 2009). Both biological 
activities, gene silencing via RNAi and stimulation of the immune system via RIG-I, can be combined 
in one molecule, the ppp-siRNA(Poeck et al., 2008). Such ppp-siRNA can be generated by in vitro 
transcription (IVT), in which a double-stranded DNA template is produced by annealing a T7 
promotor primer at the TATA-box of DNA templates of the desired genes. Templates are then 
transcribed in vitro by a T7 RNA polymerase into single-stranded ppp-siRNAs. These ppp-siRNAs 
can be applied as ligand for RIG-I to trigger pro-apoptotic signaling via the intrinsic mitochondrial 
pathway (Besch et al., 2009, Poeck et al., 2008, Ellermeier et al., 2013, Meng et al., 2013). Apoptosis 
induction affects predominantly tumor cells as non-malignant cells are protected from pro-apoptotic 
signaling via Bcl-xL (Besch et al., 2009, Meng et al., 2013). Therapeutic strategies exploiting the ppp-
siRNA technology where recently described by Ellermeier et al. and Meng et al.. Ellermeier et al. 
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could show that ppp-siRNA targeting the immunosuppressive cytokine TGF-β reduced systemic and 
tumor-associated TGF-β levels, induced type I IFNs, CXCL10 and apoptosis of tumor cells and 
activated immune cells systemically. Treatment of Panc02 tumor-bearing mice with ppp-TGF-β 
prolonged survival and led to an increase of CD8+ T cells in pancreatic tumors (Ellermeier et al., 
2013). Meng et al. generated a bifunctional ppp-siRNA targeting glutaminase (ppp-GLS). Silencing of 
glutaminase sensitized tumor cells to RIG-I, mediated apoptosis, and enhanced cytotoxicity through 
disturbed glutaminolysis (Meng et al., 2013). 
 
Objectives 
20 
3 Objectives 
PDAC is a very aggressive tumor with abundant tumor stroma and a strong immunosuppressive 
microenvironment. Further studies to clarify why T cells infiltrate the tumor but are not able to 
perform killing function as well as to find new effective therapies are urgently needed. The present 
study addressed three main goals: 
1. To characterize murine PDAC models in regards to their utility for studying immunotherapeutic 
approaches.  
2. To assess the therapeutic efficacy of a novel bifunctional ppp-siRNA that combines silencing the 
immunosuppressive molecule galectin-1 with activation of RIG-I in murine PDAC.  
3. To characterize the immunosuppressive actions on T cells in the microenvironment of PDAC. 
 
Along with advances in the generation of GEMM, new tumor models for studying PDAC have 
became available in the last years. These models have several advantages regarding phenocopying of 
the human disease. Traditionally, syngeneic tumor models have been used to study PDAC, such as 
subcutaneous or orthotopic implantation of Panc02 cells in C57BL/6 mice. With GEMM new cell 
lines have been generated for transplantation in syngeneic mice. In this study, two different GEMM 
for PDAC (KPC models) were compared with two syngeneic models (Panc02 cells and T110299 cells, 
a cell line derived from KPC mice) regarding histological appearance, expression of 
immunosuppressive molecules and growth characteristics. These studies were performed to gain 
insight into specific aspects of tumor biology for further therapeutic studies. The questions addressed 
were: How abundant is the stromal component in the tumors? Can preinvasive lesions resembling 
PanINs be detected? How are patterns of T cell infiltrations? Do the tumors express 
immunosuppressive molecules, such as galectin-1 and IDO, which can be targeted by immunotherapy?  
 
As mentioned above, PDAC express the immunosuppressive molecule galectin-1. This led to the idea 
to study siRNA molecules targeting Galectin-1 either as unmodified OH-siRNA or as modified ppp-
siRNA. Both molecules (OH-Gal-1 and ppp-Gal-1) were tested in vitro and in vivo to assess whether 
the application of siRNA and especially ppp-siRNA has therapeutic efficacy against PDAC. 
 
Pancreatic cancer is characterized by its ability to suppress T cells leading to inefficient tumor control 
by the immune system. The present study addresses several potential mechanisms for T cell inhibition, 
such as the PD-1/PD-L1 axis, galectin-1, TGF-β and IDO. Functional aspects of T cell suppression, 
such as T cell proliferation, apoptosis induction and T cell degranulation, were investigated. 
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4 Material 
4.1 Technical equipment 
Blotting system       Bio-Rad, Germany 
Cell culture CO2 incubator (BD 6220)    Heraeus, Germany 
Cell culture Laminar Flow     Thermo Scientific, Germany 
Centrifuge (Multifuge 3L-R)     Thermo Scientific, Germany 
Centrifuge (5424 and 5415R)     Eppendorf, Germany 
ELSIA reader (Mithras LB940)     Berthold Technologies, Germany 
FACSCanto II       BD Bioscience, Germany 
Gel electrophoresis system     peqlab, Germany 
Lightcycler® 480 II      Roche, Germany 
Microscope Axiovert25 and Axiovert200M   Zeiss, Germany 
Microscope TCS SP5 II     Leica, Germany 
NanoDrop® 2000c      Thermo Scientific, Germany 
pH meter       WTW, Germany 
Power Pac Basic      Bio-Rad, Germany 
Rotator RM5       Karl Hecht AG, Germany 
Scale SBC21       Scale Tec, USA 
Thermocycler T3      Biometra, Germany 
Thermomixer       Eppendorf, Germany 
Vortex Genie 2       Scientific Industries, Germany 
Water bath       Köttermann, Germany 
Western Blot analyzer (LAS4000 mini)    FujiFilm, Germany 
 
Cover glass       VWR, Germany 
Glass capillary pipette      Hirschmann Laborgeräte, Germany 
Gel blotting paper      Whatman Paper GmbH, UK 
Insulin U-100 0.3 ml      BD Microfine, Germany 
Lab-Tek® Chamber slide     Thermo Scientific, Germany 
Microscope slides (Superfrost® Plus Menzel-Gläser)  Thermo Scientific, Germany 
Nitrocellulose membrane (AmershamTM-HybondTM-ECL) GE Healthcare, Germany 
Scalpel (No. 22)      Feather, Japan 
Sutures (Prolene 5-0)      Ethicon, USA 
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4.2 Chemicals, reagents and buffers 
Alcian Blue solution (pH 2.5)     Sigma-Aldrich, Germany 
Ammonium acetate      life technologies, Germany 
Antisedan       Pfizer, USA 
Bovine serum albumin      Roth, Germany 
Catalase       Sigma-Aldrich, Germany 
Cell lysis buffer (10x)      Cell Signaling Technology, USA 
Chloroform       Roth, Germany 
Collagen (rat tail tendon)     Roche, Germany 
Collagenase        Sigma-Aldrich, Germany 
CountBrightTM absolute Counting Beads   life technologies, Germany 
3,3-diaminobenzidine (DAB)     Dako, USA 
4-dimethylamino-benzaldehyde (Ehrlich’s reagent)  Sigma-Aldrich, Germany 
DC Protein Assay (Bradford)     Bio-Rad, Germany 
Dimethyl sulfoxide      Roth, Germany 
DNase I       Roche, Germany 
Dorbene       Pfizer, USA 
DPX        Merck, Germany 
Dulbecco’s PBS (1x)      Lonza, Belgium 
Easy Coll solution (d=1.124g/l)     Biochrome, Germany 
ECL        Thermo Scientific, Germany 
Eosin Y       Merck, Germany 
Ethanol        Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA)   Sigma-Aldrich, Germany 
FACSFlow, FACSClean     BD Biosciences 
Flumazenil       Inresa, Germany 
Formal-FIXX       Thermo Shandon, UK 
Glacial acetic acid      Merck, Germany 
Heparin-Natrium Braun 25000 I.E./5 ml   Rathiopharm, Germany 
Hydrogen peroxide (H2O2, 30%)    Merck, Germany 
In vivo-JetPEITM      Polyplus transfection, USA 
Isoflurane-CP®       CP-Pharma, Germany 
Isopropanol       Applichem, Germany 
KAPA PROBE FAST Universal qPCR Master Mix  peqlab, Germany 
Lipofectamine RNAiMax     life technologies, Germany 
Lipopolysaccheride-EK, ultrapure (LPS)   InvivoGen, USA 
L-Tryptophan       Sigma-Aldrich, Germany 
Material 
23 
Mayer’s Hemalum      Roth, Germany 
Methanol       Merck, Germany 
Midazolam       Ratiopharm, Germany 
Naloxone       Inresa, Germany 
Nuclear fast red solution (0.1%)    Sigma-Aldrich, Germany 
PageRulerTM Plus Prestained Protein Ladder   Thermo Scientific, USA 
Paraformaldehyde (PFA)     Merck, Germany 
Pharmlyse       BD Bioscience, Germany 
Phenol-chlorofrom isoamyl alcohol    Sigma-Aldrich, Germany 
Potassium hydrogenphosphate     Merck, Germany 
Primer-probe mix, 10x conc.     Roche, Germany 
Propidium iodide      Sigma-Aldrich, Germany 
Proteinase K beads      Sigma-Aldrich, Germany 
Saponine       Sigma-Aldrich, Germany 
Sodium ascorbate      Sigma-Aldrich, Germany 
Sodium azide (NaN3, 10%)     Sigma-Aldrich, Germany 
Sodium chloride (NaCl 0.9%)     Baxter, UK 
Sulfuric acid (H2SO4, 2N)     Apotheke Uni Munich, Germany 
Target antigen retrieval solution (10 x, pH 6.0)   Dako, USA 
Temgesic (Buprenorphin)     RB Pharmaceuticals, UK 
TMB Substrate Reagent Set     BD Bioscience, Germany 
Trichloroacetic acid      Roth, Germany 
Trypan blue       Sigma-Aldrich, Germany 
Trypsin-EDTA(10x)      PAA, Austria 
Turbo-DNase       life technologies, Germany 
Tween® 20       Roth, Germany 
Vectashield mounting medium     Vector Laboratories, USA 
Xylene        J.T. Baker, Netherlands 
 
Western Blot: 
Laemmli buffer (6x)     Stacking buffer (4x, pH 6.8) 
347 mM SDS      248 mM Tris 
299 µM Bromphenol blue    14 mM SDS 
4.7 ml Glycerol      15 µM Bromphenol blue 
0.5 M Tris, pH 6.0     in ultrapure water 
649 mM DTT 
4.1 ml ultrapure water 
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Separating buffer (4x, pH 8.8)    Running buffer (10x) 
1.5 M Tris      248 mM Tris 
14 mM SDS      1.92 M Glycine 
in ultrapure water     35 mM SDS 
       in ultrapure water 
 
Transfer buffer (20x)     Transfer buffer (1x) 
198 mM Tris      20x stock 
2 M Glycine      10% MeOH 
in ultrapure water     in ultrapure water 
 
Blocking buffer     Washing buffer (TBST) 
5% BSA      165.9 mM Tris-HCl 
in TBST      44.5 mM Tris 
       1.5 M NaCl 
       0.5% Tween 20 
 
Immunocytochemistry: 
Fixation buffer      Permeabilization buffer 
4% PFA       0.2% TritonX-100  
in PBS       in PBS 
 
Blocking buffer 
2% BSA  
in PBS 
 
Flow cytometry: 
FACS acid buffer     Permeabilization buffer 
2 mM EDTA      0.5% saponine 
2% FBS      in PBS 
0.1% NaN3 
in PBS 
 
Fixation buffer 
1% PFA  
in PBS 
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T cell assay: 
MACS-buffer 
0.2% FBS 
2mM EDTA 
in PBS 
4.3 Cell culture reagents and media 
β-mercaptoethanol       Roth, Germany 
Dulbecco’s modified Eagls’s medium (DMEM), high glucose  Roth, Germany 
Dynabeads® Mouse T activator CD3/CD28    life technologies, Germany 
Fetal bovine serum (FBS)      life technologies, Germany 
L-glutamine (200 mM)       PAA, Austria 
MEM-NEAA (non-essential amino acids)    life technologies, Germany 
Penicilline/Streptomycin (100 x)      PAA, Austria 
Opti-MEM        life technologies, Germany 
OVA257-264 peptide (SIINFEKL)     InvivoGen, USA 
Roswell Parl memorial Institute (RPMI) 1640 medium   Biochrome, Germany 
Sodium pyruvat       Biochrome, Germany 
VLE RPMI 1640 (very low endotoxin)     Biochrome, Germany 
 
Plastic material for cell culture experiments were purchased from BD Bioscience (Germany), Corning 
(USA), Eppendorf (Germany), Greiner bio-one (Germany) or Sarstedt (Germany). 
 
Tumor cell medium      Transfection medium 
10% FBS      10% FBS 
2 mM L-glutamine      2 mM L-glutamine 
100 IU/ml penicillin      in DMEM 
100 µg/ml streptomycin 
in DMEM 
 
T cell medium       DC medium 
10% FBS       10% FBS 
2 mM L-glutamine      2 mM L-glutamine 
100 IU/ml penicillin      100 IU/ml penicillin 
100 µg/ml streptomycin     100 µg/ml streptomycin 
1 mM sodium pyruvat      1 mM sodium pyruvat 
1% MEM-NEAA      1% MEM-NEAA 
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50 µM β-mercaptoethanol     50 µM β-mercaptoethanol 
in RPMI 1640       in VLE RPMI 1640 
4.4 Cell lines 
Panc02        kindly provided by Peter Nelson lab 
T110299       kindly provided by Jens Siveke lab 
PANC-1       Cell Lines Service (CLS), Germany 
IMIM-PC1       kindly provided by Patrick Michl lab 
4.5 Kits 
Cell TraceTM CFSE Cell Proliferation kit   life technologies, Germany 
CXCL10 murine (ELSIA)     R&D Systems, Germany 
Galectin-1, murine (ELISA)     R&D Systems, Germany 
IFN-α, murine (ELISA)      R&D Systems, Germany 
HiScribeTM T7 In Vitro Transcription kit New England Biolabs GmbH, 
Germany 
LS columns       Miltenyi Biotech, Germany 
MACS Pan T cell isolation kit II    Miltenyi Biotech, Germany 
MACS CD8a T cell isolation kit II    Miltenyi Biotech, Germany 
Masson’s Trichrome Stain kit     Polyscience Inc., USA 
peqGOLD Total RNA isolation kit    peqlab, Germany 
RevertAidTM First strand cDNA Synthesis kit   Thermo Scientific, USA 
TGF-β, murine (ELISA)     eBioscience, Germany 
TNF-α, murine (ELISA)     R&D Systems, Germany 
Vectastain ABC Elite rabbit-IgG/rat-IgG kit   Vector Laboratories, USA 
4.6 Antibodies 
4.6.1 Primary conjugated antibodies and reagents for FACS 
Table 4-1: Primary conjugated antibodies and reagents for flow cytometry 
Specificity Fluorochrome Species/isotype Clone Concentration Company 
Annexin V APC chicken recombinant  1:33 Immunotools 
CD3 APC hamster/IgG1 145-2C11 1:100 BD Bioscience 
CD3 PB rat/IgG2b 17A2 1:200 BioLegend 
CD4 FITC rat/IgG2a RM4-5 1:200 BD Bioscience 
CD4 PE-Cy7 rat/IgG2a RM4-5 1:200 BioLegend 
CD4 PerCP rat/IgG2a RM4-5 1:200 BioLegend 
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CD8a APC-Cy7 rat/IgG2a 53-6.7 1:200 BioLegend 
CD8a PB rat/IgG2a 53-6.7 1:200 BioLegend 
CD8a PerCP rat/IgG2a 53-6.7 1:200 BioLegend 
CD11c APC hamster/IgG N418 1:200 BioLegend 
CD19 PE rat/IgG2a 6D5 1:200 BioLegend 
CD45R/B220 PE-Cy7 rat/IgG2a RA3-6B2 1:200 BioLegend 
CD69 FITC hamster/IgG1 H1.2F3 1:100 BD Pharmingen 
CD69 PE hamster/IgG1 H1.2F3 1:100 BD Pharmingen 
CD86 FITC rat/IgG2a GL-1 1:100 BD Pharmingen 
CD95 PE-Cy7 hamster/IgG2 Jo2 1:200 BD Pharmingen 
CD107a FITC rat/IgG2a 1D4B 1:5000 BD Pharmingen 
CD107b FITC rat/IgG2a ABL-93 1:200 BD Pharmingen 
CD274 Purified rat/IgG2a MIH5 1:200 eBioscience 
Anti-rat AF488 goat/IgG --- 1:200 life technologies 
NK1.1 PerCP mouse/IgG2a PK136 1:200 BioLegend 
MHC-I FITC mouse/IgG2a AF6-88.5 1:200 BioLegend 
MHC-II FITC mouse/IgG2a AF6-120.1 1:200 BD Pharmingen 
APC: Allophycocyanine; FITC: Fluorescein-5-isocyanate; PB: Pacific blue; PE: Phycoerythrine; PerCP: 
Peridinin-chlorophyll-protein complex;  
4.6.2 Purified antibodies for immunohistochemistry 
Table 4-2: Purified antibodies for IHC 
Specificity Species/isotype Clone Concentration Company 
α-SMA rabbit-IgG polyconal 1:400 abcam 
CD3 rabbit/IgG SP7 1:250 abcam 
CD31 rabbit/IgG polyconal 1:1.000 abcam 
Galectin-1 rat/IgG2B 201002 1:20.000 R&D Systems 
IDO rabbit/IgG polyclonal 1:50 abcam 
Isotype rabbit/IgG polyclonal depending on primary 
antibody 
abcam 
Isotype rat/IgG2B RTK4530 Biolegend 
4.6.3 Blocking antibodies 
Table 4-3: Blocking antibodies for in vitro assays 
Specificity Fluorochrome Species/isotype Clone Concentration Company 
CD279 Func. grade purified hamster IgG J43 5 µg/ml eBioscience 
CD80 Func. grade purified hamster IgG 16-10A1 5 µg/ml eBioscience 
Isotype Func. grade purified hamster IgG eBio299Arm 5 µg/ml eBioscience 
 
4.6.4 Antibodies for Western Blot 
Table 4-4: Western Blot antibodies 
Specificity Fluorochrome Species/isotype Clone Concentration Company 
pIRF3 (S396) purified rabbit/IgG 4D4G 1:1000 Cell signaling 
CD274 purified rat/IgG2a MIH5 1:1000 eBioscience 
Anti-rabbit HRP goat/IgG --- 1:2000 Santa Cruz 
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Anti-rat HRP goat/IgG --- 1:2000 Santa Cruz 
β-actin-HRP HRP mouse/IgG1 C4 1:2000 Santa Cruz 
4.7 Inhibitors 
β-lactose (Gal-1)       Sigma-Aldrich, Germany 
Celecoxibe (COX2)       Sigma-Aldrich, Germany 
D-1-Methyltryptophan (D-1-MT) (IDO)    Sigma-Aldrich, Germany 
SC-560 (COX1)       Sigma-Aldrich, Germany 
SD-208 (TGF-βRI)       TOCRIS bioscience, USA 
Thiodigalactoside (Gal-1)      Carbosynth, UK 
4.8 Recombinant cytokines and proteins 
Interleukin-2 (IL-2), mouse      Peprotech, Germany 
Interleukin-4 (IL-4), mouse      Peprotech, Germany 
Interferon α (IFN-α), mouse      Miltenyi Biotech, Germany 
Interferon β (IFN-β), mouse       
Interferon γ (IFN-γ), mouse      Immunotools, Germany 
GM-CSF, mouse        Peprotech, Germany 
Galectin-1, mouse       R&D Systems, Germany 
TGF-β, human/mouse       R&D Systems, Germany 
4.9 siRNA sequences 
Table 4-5: siRNA sequences for RNAi 
gene sequence (5’->3’) 
OH-RNA (control) GCGCTATCCAGCTTACGTATT 
Galectin-1 GAUGGAGACUUCAAGAUUAUU 
TGF-β1 GAACUCUACCAGAAAUAUAUU 
RIG-I GAAGCGUCUUCUAAUAAUU 
4.10 DNA-template sequences for in vitro transcription 
Table 4-6: DNA-template sequences for IVT 
gene sequence (5’->3’) 
OH-RNA (control) GCGCTATCCAGCTTACGTAGAGCTCTACGTAAGCTGGATAGCGCTATAGTGAGTCGTA 
Galectin-1 GATGGAGACTTCAAGATTACTCGAGTAATCTTGAAGTCTCCATCTATAGTGAGTCGTA 
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4.11 Primer sequences for qRT-PCR 
Table 4-7: Primer sequences for qRT-PCR 
gene 
 
5’->3’ 
Galectin-1 left CTCTCGGGTGGAGTCTTCTG 
right GGTTTGAGATTCAGGTTGCTG 
Interferon β left ACTGCCTTTGCCATCCAA 
right CCCAGTGCTGGAGAAATTGT 
TGF-β1 
left TGGAGCAACATGTGGAACTC 
right CAGCAGCCGGTTACCAAG 
IDO left GCACTCAGTAAAATATCTCC 
right CTAAGGCCAACTCAGAAGA 
HPRT left GGAGCGGTAGCACCTCCT 
right CTGGTTCATCATCGCTAATCAC 
4.12 Software 
Adobe Photoshop CS4      Adobe Systems, USA 
Adobe Illustrator CS4      Adobe Systems, USA 
Axiovision Rel.4.4      Zeiss, Germany 
EndNote X4       Thomson Reuters, USA 
FACSDiva       BD Bioscience, Germany 
FlowJo 7.6.5       Tree Star, USA 
Graphpad Prism 5.0      Graphpad Software, USA 
Image J       Image J Software, USA 
LAS AF V2.2.1      Leica, Germany 
Lightcycler 480 SW 1.5     Roche, Germany 
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5 Methods 
5.1 Tumor cell culture 
All tumor cell lines were cultured in DMEM complete medium in tissue culture flasks (T75) at 37°C 
in 10% CO2 and 95% humidity. 
 
All manipulations were performed with sterile reagents under a laminar flow hood. Cell number and 
viability was determined by Trypan blue staining. Cell suspensions were mixed with 0.5% Trypan 
blue in PBS at appropriate dilutions and counted in a Neubauer hemocytometer under the microscope. 
5.2 Immunological methods 
5.2.1 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a method to detect cytokines or other proteins in samples from in vitro or in vivo assays by 
enzyme-linked antibodies. Proteins of interest in samples were bound by the respective plate-bound 
capture antibody followed by a second, biotinylated detection antibody which will bind streptavidin 
coupled to a horse radish peroxidase (HRP). This enzyme catalyzes the oxidation of 3,3’,5,5’ – 
tetramethylbenzidine (TMB) with hydrogen peroxide to a blue chromogen. 
 
The detection of the chemokine CXCL10, the cytokine TGF-β and the protein Galectin-1 was 
performed with kits including all necessary reagents according to the manufacturer’s instructions. Cell 
culture samples for CXCL10 were diluted 1:2, and undiluted for TGF-β. Serum samples for Galectin-
1, IFN-α and TNF- α were diluted 1:5, for CXCL10 samples were diluted 1:10. 
5.2.2 Western Blot 
Cells were washed twice with cold PBS and lysed in an appropriate volume of lysis buffer for 30 min 
on ice. Samples were spun down for 10 min at 14 000 g, 4°C. The supernatant was transferred to a 
fresh Eppendorf tube and the protein concentration was determined by Bradford assay. Samples were 
mixed with 6 x Laemmli buffer and incubated at 95°C of 5 min. 50 µg whole cell lysate of each 
sample was loaded on a 10-15 % SDS gel, depending on the size of the protein of interest. As a 
standard, 5 µl of PageRulerTM Plus Prestained Protein Ladder (Thermo Scientific) was loaded. The gel 
was run at 100 V for 90 min. Proteins were transferred to a nitrocellulose membrane using the Mini 
Trans-Blot® Electrophoresis Transfercell (Biorad) in 1 x transfer buffer. The electrophoretic transfer 
was performed at 350 mA for 60 min at RT. Membranes were blocked with 5% BSA/TBST for 60 
min at RT. Primary antibodies were diluted in blocking solution and incubated overnight at 4°C with 
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gentle shaking. Afterwards they were washed with TBST three times for 10 min and then incubated 
with the appropriate secondary antibody for 60 min at RT rotating. Membranes were washed three 
times for 10 min with TBST and developed using chemiluminescence substrate ECL (Thermo 
Scientific), according to the manufacturer’s instructions. The membranes were exposed with the 
Western Blot analyzer LAS4000 mini. 
5.2.3 Histology 
5.2.3.1 Fixation, paraffin embedding and microtoming of mouse tumors 
Organs were fixed in 10% phosphate-buffered formalin (Thermo Shandon) overnight at RT, followed 
by 9 h automated processing with a series of dehydration steps, and then they were embedded in 
paraffin wax. Paraffin blocks were sectioned with a microtome and 5 µm sections were floated on a 
water bath at 50°C, transferred to glass slides, dried overnight at 37°C and stored at RT until staining. 
5.2.3.2 Hematoxylin and eosin staining 
The general immunohistochemistry protocol for paraffin embedded tissue sections included the 
following steps. Paraffin-embedded sections were deparaffinized by two rinses with xylene for 15 min 
and three rinses with alcohol (100, 96, and 70%, each 3 min), followed by two rinses in distilled water 
for 5 min. Afterwards, the nuclei were stained with Mayer’s hemalaun coloring nuclei blue, followed 
by a 5 min washing step under running tap water. Then, a 1 min counter staining with an alcoholic 
solution of eosin Y coloring the cytoplasm and eosinophilic structures in various shades of red, pink 
and orange was performed and rinsed with tap water three to four times. Finally, the sections were 
dehydrated in an increasing ethanol series (two times 95% and 100%, each 5 min) and twice in xylene 
for 15 min followed by mounting the sections with xylene based DPX. 
5.2.3.3 Masson’s Trichrome staining 
Staining of collagen fibers to visualize tumor stroma was performed with the Masson’s Trichrome 
Staining kit according to the manufacturer’s instructions. Briefly, paraffin embedded sections were 
rehydrated and mordant in Bouin’s solution for 1 min at 750W in a microwave and cooled down for 
15 min at RT. Sections were washed in running tap water for 5 min with a subsequent staining of 
nuclei with Weigert’s hematoxylin for 7 min (nuclei colored blue), washed under running tap water for 
5 min and rinsed in distilled water. Afterwards, cytoplasm and erythrocytes were stained with Biebrich 
Scarlet-Acid Fuchsin solution for 5 min and slides were rinsed in distilled water. To allow uptake of 
Aniline Blue, sections were placed in Phosphomolybdic/Phosphotungstic Acid Solution for 10 min 
and directly transferred to Aniline Blue for 7 min (blue staining of collagen) and rinsed in distilled 
water. Finally, sections were placed into an 1% Acetic acid solution for 3 min to render the shades of 
color more delicate and transparent and after the dehydration to xylene they were mounted with DPX. 
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5.2.3.4 Alcian Blue staining 
The Alcian Blue 8G dye is a basic dye, which preferably stains acid mucosubstances and acetic 
mucins when given the right pH and salt concentrations. The presumed basis of the staining is its 
positive charge attracted to negative structures (e.g. acidic sugars), bulkiness (width 2.5–3 nm, 
compared to toluidine blue ~0.7 x1.1 nm (Toluidine)), which makes its diffusion very slow in less 
permeable parts of the tissue and thus prevent it from staining highly negative compact structures such 
as chromatin (DAKO). Precursor lesions of pancreatic cancer (PanIN) show strong accumulation of 
acetic mucins. Strongly acidic mucosubstances will be stained blue, nuclei become visible pink to red 
and cytoplasm will be stained pale pink. Formalin-fixed paraffin embedded tumor sections were 
deparaffinized and hydrated to distilled water. Staining with Alcian Blue solution (pH 2.5) for 30 min 
with a subsequent washing step for 2 min under running tap water was performed. Sections were 
rinsed in distilled water, counterstained in 0.1% nuclear fast red solution for 5 min and washed for 1 
min in running tap water. After dehydration to xylene, sections were mounted in xylene based DPX. 
5.2.3.5 Immunohistochemistry 
The method employed in this work is the Avidin-Biotin-Complex (ABC) method. This technique uses 
the strong binding affinity of avidin to biotin. Three steps are involved. Firstly, a purified and 
unlabeled primary antibody binds the specific antigen in the tissue section. Secondly, a biotinylated 
secondary antibody reacts with the primary antibody and thirdly an avidin-coupled peroxidase binds 
specifically to biotin in order to form a strong avidin-biotin-peroxidase complex. To visualize the 
complex, a specific substrate like DAB (3,3’-diaminobenzidine, brown), AEC (3-amino-9-
ethylcarbazole, red) or TMB (3,3’ 5,5’ tetramethyl benzidine, blue) can be used to develop the 
peroxidase producing different colorimetric end products. The detection systems used within this 
study were Vectastain ABC Elite rabbit-IgG and rat-IgG kit with DAB as a substrate for the 
peroxidase.  
 
The general immunohistochemistry protocol includes the following steps. Deparaffinization of the 
tissue sections with xylene twice 15 min, rehydration in a decreasing ethanol series (100, 95 and 70%, 
each 3 min) and washing twice 5 min in distilled water. For some antibodies it is necessary to unmask 
their specific antigens. The tissue sections were dunked into sodium citrate buffer, pH 6.0 and 
microwaved 30 min at 750W. Evaporated buffer had to be replaced after the first 15 min. The slides 
were cooled down for 20 min at RT and washed twice with PBS for 5 min. Blocking of endogenous 
peroxidases was performed by incubation in 7.5% hydrogen peroxide (H2O2) for 10 min, followed by 
a 10 min washing step with tap water and two times PBS for 5 min. Afterwards, sections were blocked 
with normal serum from two different Vectastain ABC Elite kits (see chapter 4.5) for 20 min and 
incubated with the appropriate primary antibody, diluted in blocking buffer in a humidified chamber 
(Incubation times for the different primary antibodies differed in some aspects, see Table 5-1. 
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Table 5-1: Incubation times of primary antibodies in immunohistochemistry 
Antibody Detection system Incubation time Incubation temperature Dilution 
α-SMA rabbit-IgG 1 hour RT 1:400 
CD3 rabbit-IgG overnight 4°C 1:250 
CD31 rabbit-IgG overnight 4°C 1:1.000 
Galectin-1 rat-IgG 1 hour 37°C 1:20.000 
IDO rabbit-IgG overnight 4°C 1:50 
Isotype rabbit-IgG depending on primary antibody 
Isotype  rat-IgG2b depending on primary antibody 
 
Binding of the primary antibodies was followed by some washing steps with PBS/0.05% Tween 20 
and PBS (each 5 min) and 30 min incubation with biotinylated secondary antibody. After washing 
with PBS/0.05% Tween 20 and PBS (each 5 min), antibody binding was detected using the Vectastain 
Elite ABC reagent (avidin coupled peroxidase) following the instructions of the manufacturer. Finally, 
the sections were counterstained with Mayer’s hemalaun for 90 sec, washed 5 min with tap water and 
rinsed 2 min in distilled water. Dehydration of the tissue sections was performed by increasing ethanol 
series (95%, 100% each twice 5 min) and twice 15 min xylene. Slides were covered with xylene based 
mounting medium DPX, dried overnight and analyzed using the Axiovert200M. 
5.2.3.6 Immunocytochemistry 
Panc02 cancer cells (1*104 per well) were seeded over night at 37°C in a sterile chamber slide, which 
was coated before with rat tail tendon collagen (1:100 with distilled water) for 1 h at 37°C. Cells were 
fixed with 4% paraformaldehyde (PFA) for 10 min at 37°C and permeabilized with 0.2% TritonX-100 
for 15 min at RT. Afterwards, cells were blocked with 2% BSA for 30-60 min at RT (or overnight at 
4°C). Primary antibodies in blocking solution were incubated for 60 min at RT, followed by a 45 min 
incubation of secondary antibody in blocking solution. Nuclei were stained with Hoechst-stain (1:200) 
for 5 min at RT. After every step, a washing step with PBS followed. Finally, the chamber was 
removed from the slide and cells were coverslipped with Vectashield mounting medium. Slides could 
be stored at -20°C until analysis with confocal microscopy (TCS SP5 II). 
5.2.4 Flow cytometry 
The detection of surface molecules as well as intracellular molecules can be done with directly 
fluorochrome labeled primary antibodies or with unlabeled primary antibodies, which than can be 
detected by fluorochrome-labeled secondary antibodies. The different emissions of the fluorochromes 
can be detected by flow cytometry (FACS). Additionally, the refracted light from cells is detected and 
therefore the size and granularity of cells can be determined. 
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Table 5-2: Spectral properties of the used fluorochromes in flow cytometric experiments 
Fluorochrome Excitation peak  [nm] 
Emission peak  
[nm] 
Laser 
FACSCanto II [nm] 
Filter 
FACSCanto II 
APC 650 660 633 660/20 
APC-Cy7 650 785 633 780/60 
CFSE 492 517 488 530/30 
FITC 495 525 488 530/30 
Pacific blue 404 455 405 450/50 
PE 564 575 488 585/42 
PE-Cy7 564 767 488 780/60 
PerCP 482 678 488 670 
PI 493 619 488 610/20 
 
The analysis was made with the flow cytometer BD FACSCantoII, which uses three different lasers: a 
blue laser (488 nm, air-cooled, 20 mW solid state), a red laser (633 nm, 17 mW HeNe) and a violet 
laser (405 nm, 30 mW solid state). These lasers with their adequate filter bands give the possibility to 
measure emissions of different fluorochromes at the same time. One has to pay attention that the 
spectral overlap of the emissions of the used fluorochromes is as low as possible. In a simultaneous 
analysis the compensation of the different emissions has to be done by samples, which are separately 
stained with each fluorochrome. With the help of the compensation controls, positive and negative 
populations can be detected and used to define the exact compensation level by hand or with the help 
of software (BD FACSDiva). Staining of the compensation controls was done by using the same cells 
as in the sample itself. These cells were washed once with 200 µl FACS acid buffer and then stained 
with the fluorescent labeled antibody in the same dilution as in the sample to be analyzed. The controls 
were incubated for 30 min at 4°C in the dark. The measuring procedure could take place after a final 
washing step with 200 µl FACS acid buffer. 
5.2.4.1 Surface staining 
For the surface staining, cells were distributed in a 96-well-plate or in FACS tubes and washed once 
with FACS acid buffer. Afterwards, cells were resuspended in buffer and spun down for 5 min at 
400g. The supernatant was discarded and staining with the antibodies was performed. The dilution of 
each antibody was tested before and the right volume was pipetted to the cell suspension. The samples 
were mixed with a multi channel pipette and incubated for 30 min at 4°C in the dark. Finally, cells 
were washed with 200 µl FACS acid buffer and resuspended in 150 µl for analysis. 
 
If the cells were not measured immediately after the surface staining, the cells would have been fixed 
with 200 µl of 1% paraformaldehyde (PFA). The cells were incubated darkened for 20 min at 4°C and 
afterwards washed with 200 µl PBS. 
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5.2.4.2 Intracellular staining 
To achieve an intracellular staining, the antibodies have to pass the cell membrane. Therefore, cells 
were permeabilized with 200 µl of 0.5% saponine solution for 20 min at 4°C. The antibodies were 
pipetted into 0.5% saponine solution and incubation was done for 30 min at 4 °C in the dark. If the 
primary antibody was unlabeled, a secondary fluorochrome-labeled antibody would be added after a 
washing step with 0.5% saponine solution. After an incubation time of 30 min the cells were washed 
with 200 µl FACS acid buffer and fixed using 200 µl 1% PFA. The cells were stored in 1% PFA until 
the measurement was done. 
5.2.5 T cell assays 
5.2.5.1 T cell proliferation assay 
Isolated untouched Pan T cells (chapter 5.4.2.2) were labeled with CFSE using the Cell TraceTM CFSE 
Cell Proliferation Kit, a cell-tracing reagent (carboxyfluorescein diacetat succinimidyl ester), which 
diffuses passively into cells. The label is inherited by daughter cells after each cell division. Isolated T 
cells were washed twice with PBS and resuspended in 5 ml PBS. 2.5 µl 5 mM CFSE (final 2.5 µM) 
was mixed with 5 ml PBS and added to the T cells. After incubation for 4 min at RT labeling was 
stopped with 50 ml PBS/10%FBS, centrifuged for 5 min at 400g and resuspended in T cell medium. T 
cells were then mixed with mouse T-activator CD3/CD28 Dynabeads® to stimulate their proliferation 
by mimicking in vivo T cell activation from antigen-presenting cells. Beads were washed in T cell 
medium and mixed 5 sec on a vortexer. Due to magnetic properties of DynaBeads, they were placed 
into a magnetic field for 1 min to remove supernatant. Dynabeads were resuspended in the same 
volume as before and mixed with the T cell suspension. In this assay, 1x105 T cells were incubated 
with 2 µl of CD3/CD28 Dynabeads® in a final volume of 200 µl medium in a 96-well-plate for 72 h at 
37°C. Afterwards, proliferation of T helper cells (CD3+CD4+) and cytotoxic T cells (CD3+CD8+) in 
the absence or presence of defined concentrations of tumor supernatant was analyzed by flow 
cytometry (CFSE dilution method). 
5.2.5.2 T cell degranulation assay 
In the degranulation assay the proteins CD107a (LAMP-1) and CD107b (LAMP-2) can be tapped with 
the help of fluorochrome conjugated antibodies on the cell surface. CD107a and CD107b are 
lysosomal membrane proteins, which reach the cell surface when cytotoxic T cells or NK cells 
exocytose their lytic granules after contact with target cells. Isolated CD8+ T cells from spleens of OT-
1 mice were preincubated with 50% tumor supernatant of Panc02 and T110299 cells or T cell medium 
for 2 h at 37°C. After that, the pretreated T cells were separated into two different stimulation 
conditions, DC without peptide and DC pulsed with SIINFEKL peptide. The ratio of SIINFEKL-DC 
and T cells was 1:2. Additionally, in each condition 0.1 µg CD107a-FITC and 0.5 µg CD107b-FITC 
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antibody was added. Each condition contained 5*105 T cells per well in a 96-well plate with or 
without 25% tumor supernatant and in the absence or presence of DCs for 5 h at 37°C. The CD107 
antibodies in the incubation conditions marked CD107 molecules which had reached the cell surface. 
After 5 h, the degranulation was stopped by adding FACS acid buffer and staining of the surface 
marker CD8 and additional CD107a and CD107b was performed. 
5.3 Molecular biology methods 
5.3.1 In vitro transcription 
siRNA against galectin-1 was designed according to published guidelines and was purchased from 
Eurofins MWG Operon (Reynolds et al., 2004). 5’ppp-modified siRNA was established by in vitro 
transcription (IVT). The DNA template used to generate a triphosphate hairpin siRNA targeting 
galectin-1 had the following sequence: 
5’GATGGAGACTTCAAGATTACTCGAGTAATCTTGAAGTCTCCATCTATAGTGAGTCGTA3’ 
The green sequence consists of nucleotides, which are responsible for galectin-1 gene silencing. The 
red nucleotides form the hairpin structure and the blue nucleotides are the TATA-box to anneal the T7 
promotor primer sequence. 
 
The first step of the IVT procedure was to prepare DNA template for transcription. This step consisted 
of the annealing of the T7 promotor primer to the DNA template and the synthesis of a double 
stranded DNA template. For the annealing step, the same amount of DNA template and T7 promotor 
primer plus DNA hybridization buffer was pipetted to a final volume of 14 µl and incubated for 10 
min at 75°C with subsequent incubation for 1 h at RT for cooling. The synthesis of double stranded 
DNA was performed using the Exo-Klenow DNA polymerase (14 µl Template, 2 µl Klenow Fill-In 
buffer (10x), 2 µl dNTP mix (2.5 mM) and 2 µl Exo-minus Klenow DNA polymerase (10 U/µl)). 
After incubation at 37°C for 30 min, the Exo-minus Klenow DNA polymerase was inactivated by 
heating it for 10 min at 75°C. The second step of the IVT procedure was the IVT itself, which was 
done with the HiScribeTM T7 In Vitro Transcription Kit according to the manufacturer’s protocol for 
short templates (50-300 nucleotides). Incubation took place for 6 h at 42°C. The last step was to 
isolate the 5’modified ppp-RNA, which was subdivided into three steps. The first step included the 
digestion of DNA using DNaseI. 2 µl of Turbo-DNase were added to the IVT preparation for 30 min 
at 37°C. Afterwards, 30 µl of ammonium acetate were added, mixed well and the tube was washed 
with 230 µl PCR-grade water. In the second step, the RNA was purified by phenol-chloroform 
extraction, followed by the precipitation of the RNA adding twice the volume of 99% ethanol and by 
incubation at -20°C over night. The third and last purification step started with a 30 min centrifugation 
at 14.000 rcf at 4°C to pellet the RNA. After drying, the RNA was resuspended in 100 µl PCR-grade 
water and further purified by Mini quick spin columns. Finally, the amount of 5’ppp-RNA was 
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measured photometrically using the Nano Drop® and tested in vitro for its stimulation ability 
(induction of CXCL10, apoptosis or up-regulation of MHC-I expression on tumor cells). 
5.3.2 Transfection of siRNAs 
In vitro transfection of tumor cells was performed using Lipofectamine RNAiMAX. One day before 
transfection, cells were plated in a medium without antibiotics. A 50 to 60% confluence at the time of 
transfection was recommended. The Lipofectamine-siRNA-complexes were prepared in two separate 
Eppendorf tubes. The siRNA (50 µl per well) as well as the transfection reagent Lipofectamine 
RNAiMAX (50 µl per well) was diluted in Opti-MEM medium and incubated for 5 min at RT. After 
incubation, Lipofectamine RNAiMAX was mixed 1:1 with the siRNA and incubated for another 
twenty min at RT to build up liposome complexes. Finally, 100 µl of complexes were added to each 
well containing cells and 1400µl medium for 6-well plates. 
5.3.3 RNA isolation 
RNA isolation was performed using the peqGOLD Total RNA isolation kit from peqlab according to 
the manufacturer’s instructions. Samples were first lysed and homogenized in the presence of a highly 
denaturing guanidine-thiocyanate-containing buffer, which immediately inactivates RNases to ensure 
purification of intact RNA. As a second step, samples were applied to a DNA removing column and 
afterwards mixed with the same volume of 70% ethanol, in order to provide appropriate binding 
conditions. The sample was then applied to a PerfectBind RNA column, where the total RNA binds to 
the membrane and where contaminants were efficiently washed away with two different washing 
buffers. Subsequently, RNA was than eluted in 50 µl RNase free water. The procedure provides 
enrichment for mRNA since most RNAs <200 nucleotides (rRNA, tRNA) are selectively excluded. 
The concentration of total RNA was determined photometrically by Nano Drop®. 
5.3.4 cDNA transcription 
cDNA transcription was done with the RevertAIDTM First strand cDNA Synthesis kit from Thermo 
Scientific according to manufacturer’s instructions. The kit used the RevertAidTM M-MuLV reverse 
transcriptase for cDNA synthesis and the RiboLockTM RNase inhibitor to protect RNA from 
degradation. Oligo(dT)18 primer, which anneal selectively to the 3’-end of poly(A)RNA, were used to 
synthesize cDNA only from poly(A) tailed mRNA. 
 
In the first step, 0.1 ng – 5 µg of the isolated RNA was incubated for 60 min at 42°C for amplification 
with the following components: 1 µl oligo(dT)18 primer, nuclease-free water to a final volume of 12 
µl, 4 µl Reaction Buffer (5x), 1 µl RiboLockTM RNase inhibitor (20 U/µl), 2 µl dNTP mix (10 mM) 
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and 1 µl RevertAidTM M-MuLV reverse transcriptase (200 U/µl). The reaction was terminated by 
heating at 70°C for 5 min. 
5.3.5 Quantitative real time – polymerase chain reaction 
Real-time PCR is a quantitative PCR method for the determination of the copy number of PCR 
templates such as DNA or cDNA in a PCR. It monitors the increase of cDNA as it is amplified via 
fluorescence, which is emitted during the reaction and functions as an indicator. The method used in 
this work is the probe-based PCR, which requires in addition to PCR primers a fluorochrome-labeled 
probe, which is an oligonucleotide with both, a fluorescent reporter at one end, and a quencher of 
fluorescence, at the opposite end. The 5’3’ activity of the Taq polymerase breaks down the probe 
resulting in the breakdown of the reporter-quencher proximity which allows unquenched emission of 
fluorescence. An increase in the product targeted by the reporter probe at each PCR cycle therefore 
causes a proportional increase in fluorescence due to the breakdown of the probe and release of the 
reporter. 
 
For the PCR reaction the KAPA PROBE FAST qPCR Kit from peqlab was used. The appropriate 
gene primers were generated with respect to the Roche Library as the probes were purchased from 
Roche. The procedure was performed according to the manufacturer’s instructions except for the total 
volume of each approach, which was scaled down from 20 µl to 10 µl, summarized in Table 5-3. 
Table 5-3: Components for one RT-PCR approach 
Content Function Volume/well [µl] 
Water, PCR-grade Adjust the final reaction volume 1,5 
KAPA PROBE FAST Universal 
qPCR Master Mix (2X) 
KAPA Taq HotStart DNA 
polymerase, KAPA PROBE FAST 
qPCR buffer, dNTP mix and 5 mM 
MgCl2 and stabilizers 
5,0 
Primer forward [100µM]  1:10 diluted 0,2 
Primer reverse [100µM] 1:10 diluted 0,2 
Probe mix, 10x conc.  0,1 
 
The detection format was ‘mono color hydrolysis probes’ and the program setting described in Table 
5-4 was used. The analysis was done by LightCycler® 480 software Version 1.5. 
Table 5-4: program setting 
Program name Cycles Analysis mode Temperature [°C] 
Pre-incubation 1 none 95 
Amplification 45 quantification 60 
Cooling 1 None 40 
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5.4 Animal experiments 
5.4.1 Animals 
C57BL/6 mice were purchased from Janvier (St. Berthevin Cedex, France). Transgenic OT-I mice 
were kindly provided by Dr. Reinhard Obst (Institute of Immunology, Ludwig-Maximilian University 
Munich, Germany). 
 
The mice were 6 to 10 weeks of age at the onset of experiments. They were anesthetized with 
isoflurane for blood withdrawal and subcutaneous (s.c.) tumor cell inoculation. For orthotopic tumor 
cell inoculation into the pancreas, mice were narcotized with 100 µl narcotic mixture intraperitoneal 
(i.p.) (Table 5-5) and antagonized with 100 µl i.p. and 100 µl s.c. antidote (Table 5-6). All animal 
studies were approved by the local regulatory agency (Regierung von Oberbayern, Munich, Germany), 
animal experimentation application number for Galectin-1 experiments 55.2-1-54-2531-143-09, and 
orthotopic tumor transplantation of T110299 were performed under the experimentation application 
number 55.2-1-54-2532-175-12. 
Table 5-5: Narcotic mixture for orthotopic tumor cell injection 
Name concentration Mass Function 
Midazolam 5 mg/ml 10 mg Benzodiazepine; sedation 
Temgesic (Buprenorphin) 0.3 mg/ml 0.3 mg Opioide; analgic 
Dorbene (Medetomidine) 
 
1 mg/ml 0.2 mg α2 adrenergic agonist; 
sedation, analgic 
 
Table 5-6: Antidote mixture for orthotopic tumor cell injection 
Name concentration Mass Function 
Flumazenil 0.1 mg/ml 0.5 mg Benzodiazepine receptor 
antagonist 
Naloxone 0.4 mg/ml 1.2 mg Opioide inverse agonist 
Antisedan (Atipamezole) 5 mg/ml 2.5 mg α2 adrenergic antagonist 
 
5.4.2 Organ and single cell preparation 
5.4.2.1 Preparation of serum and isolation of peripheral blood mononuclear cells 
For the detection of Galectin-1 in the serum, blood was collected from the retro-orbital sinus with a 
glass capillary pipette. To collect serum, 300 µl of blood was collected in an Eppendorf tube and 
centrifuged at 1000g for 10 min. Serum (the supernatant) was carefully taken and stored at -20°C until 
further analysis. For the collection of PBMCs, 300 µl blood were collected in an Eppendorf tube 
containing 50 µl heparin, mixed immediately, and kept on ice. 1 ml of PharmLyse ammonium chloride 
buffer (1x) was added to lyse erythrocytes, and samples were incubated for 5 min at RT before being 
transferred into a falcon tube with 10 ml PBS with subsequent centrifugation (400g, 5 min) and 
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washed with PBS to remove remaining lysed red blood cells. Cells were then stained with 
fluorochrome-labeled antibodies and analyzed by flow cytometry. 
5.4.2.2 Isolation of T cells from mouse spleen 
For the isolation of mouse T cells (untouched Pan or CD8+ T cells), the MACS T cell isolation kit 
from Miltenyi Biotech was used according to manufacturer’s instructions. This system is used for the 
isolation of untouched T cells from mouse spleen or lymph nodes. The principle is negative selection 
by depleting the cell suspension of non-T cells or CD8+ T cells (CD4+ T cells, NK cells, B cells, 
dendritic cells, macrophages, granulocytes and erythroid cells). In a first step, a single cell suspension 
was prepared. To remove cell clumps from dissected splenocytes the cell suspension was passed over 
a 40 µm nylon mesh. Cells were spun down for 5 min at 400g, resuspended in 5 ml lysing buffer to 
remove erythrocytes and incubated for 5 min at RT. After adding 50 ml PBS, cells were spun down for 
5 min at 400g and washed with MACS-Buffer. A further washing step followed and then, cells were 
counted and resuspended in MACS-Buffer, 40 µl per 107 cells. Next, non-T cells or -CD8+ T cells 
were magnetically labeled to biotin-conjugated monoclonal antibodies with 10 µl antibody-cocktail 
(CD8 T cell isolation kit, (Miltenyi Biotech) or Pan T cell isolation kit (Miltenyi Biotech)) per 107 
cells and incubated on ice for 15 min. The antibodies included in the CD8 T cell isolation kit are 
directed against CD4, CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, Anti-MHC 
class II, and Anti-Ter-119, whereas the Pan T cell isolation kit lacks the CD4 antibody. Again 30 µl 
per 107 cells MACS-buffer was added. In a second step, 20 µl per 107 cells anti-biotin labeled 
monoclonal antibodies, conjugated to MicroBeads, were added and incubated 20 min on ice. After a 
further washing step with MACS-buffer the cell suspension was passed through a MACS column (LS 
column for up to 108 labeled cells) in a magnetic field where magnetically labeled non-T cells or -
CD8+ T cells were bound to the column. The unlabeled Pan T cells or CD8+ T cells passed through the 
column (negative fraction). The purity of isolated T cell populations was checked by flow cytometric 
analysis. 
5.4.2.3 Generation of bone marrow-derived dendritic cells 
Bone marrow-derived dendritic cells (BMDCs) were isolated from murine tibia and femur. After 
removing muscles, bones were put in 70% ethanol for 2 min. Epiphyses were cut off and bones were 
flushed with a culture medium with a syringe. Bone marrow cells were flushed through a 40 µm mesh 
and centrifuged for 5 min at 400 g. Supernatant was discarded and cell suspension was depleted from 
erythrocytes with 3 ml of red cell lysis buffer for 3 min. After another centrifugation step for 5 min at 
400g, cells were resuspended in 15 ml medium mixed with 20 ng/ml of murine GM-CSF and 20 ng/ml 
of murine IL-4, plated in 6-well plate and incubated at 37°C for six to seven days. Medium was 
changed every two days. One day before using the cells 1 µg/ml lipopolysaccharide (LPS) was added 
to activate the DC. 
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5.4.3 In vivo experiments 
5.4.3.1 Tumor models 
Before injecting tumor cells s.c. or orthotopically, cells had to be prepared by washing three times 
with PBS to remove fetal calf serum. 
 
For s.c. tumor models, 5*105 Panc02 and 9*105 T110299 cancer cells were injected in a volume of 
100 µl PBS. Tumor growth was measured every two days with a caliper rule. Mice were sacrificed 
when tumor size reached 150 mm2, tumors ulcerated or mice were distressed. 
 
Orthotopic tumors were induced by surgical implantation of 2*105 Panc02 and 4*105 T110299 cancer 
cells in 40 µl PBS into the tail of the pancreas after narcotization of mice as described in chapter 5.4.1. 
Eyes were protected from drying with a salve for eyes and noses (Bepanthen®, Bayer Vital GmbH, 
Leverkusen, Germany). After tumor cell injection, peritoneum and skin were sutured with Prolene 5-0 
(Ethicon). The antidote (Table 5-6) was administered (100 µl i.p., 100 µl s.c.) and the mice were kept 
under red light until every mouse had wakened up. Postoperative analgesia was performed per 
protocol and mice were regularly checked for signs of distress. 
5.4.3.2 Therapy with siRNAs 
50 µg OH-RNA or OH-Gal-1 siRNA was complexed with in vivo-JetPEI at an N/P ratio of 6 in 5% 
glucose solution for tail vein injection. siRNAs were injected as indicated in the experiments. For 
survival experiments, a therapeutic application of RNA (OH-RNA, OH-Gal-1, ppp-Gal-1) was 
performed twice weekly over three weeks. 
5.5 Statistical analysis 
Data represent mean plus standard deviation (SD) for in vitro data or standard error of the mean 
(SEM) for in vivo data. Significant differences were analyzed by unpaired, one-way analysis of 
variance (ANOVA), including Bonferroni correction (multiple comparisons). Survival curves were 
analyzed with the Mantel-Cox test. Statistical analysis was conducted using GraphPad Prism software 
(version 5.02); P-values <0.05 were considered significant. 
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6 Results 
6.1 Histological characterization of murine pancreatic cancer models 
Four different murine pancreatic cancer models were characterized by histology: two syngenic models 
induced orthotopically in the pancreas of C57BL/6 mice (Panc02 and T110299) and two GEMM 
based on mutant Kras and p53 (Pdx-1-Cre, LSL-KrasG12D/+, LSL-Trp53R172H/+, thereafter named KPC; 
and Pdx-1-Cre, LSL-KrasG12D/+, LSL-Trp53fl/-, thereafter named KPfC). The T110299 cell line was 
generated from primary tumors of KPC mice. 
 
The general composition of the tumors was visualized via hematoxylin and eosin (H&E) staining. 
Additional staining analyzed collagen composition to study tumor stroma, blood vessel formation and 
PanIN precursor lesions of PDAC. Tumor infiltrating T cells, the expression of Galectin-1 and IDO 
were analyzed by IHC.  
6.1.1 H&E staining 
Histological analysis of orthotopic Panc02 tumors (Figure 6-1 A and B) revealed a poorly 
differentiated morphology with large areas of necrosis in the tumor center (asterisk) and a sarcomatoid 
architecture. In contrast, orthotopic T110299 tumors (Figure 6-1 C and D) showed a moderately well-
differentiated morphology organized in glandular structures typical for adenocarcinoma (arrows). 
Tumors from KPC mice (Figure 6-1 E and F) as well as KPfC mice (Figure 6-1G and H) demonstrated 
a well-differentiated morphology organized in glandular architecture with abundant tumor stroma 
(arrowhead), closely resembling human disease. Figure 6-1 E revealed early pancreatic tumors (arrow) 
in the head of the pancreas in close proximity to duodenum (asterisk). The star marks acinus cells of 
the pancreas. The biological difference between both GEMM is that KPfC mice develop 
adenocarcinomas (Figure 6-1 G and H asterisk) much earlier than KPC mice (Mazur and Siveke, 
2011), which showed at the time of necropsy mainly PanIN lesions (Figure 6-1 F asterisk). 
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Figure 6-1: H & E staining of murine primary pancreatic carcinoma models. 
H&E staining performed for orthotopic Panc02 (A and B) and T110299 (C and D) tumor model, as well as 
primary KPC and KPfC tumors (E-H). A and B: poorly differentiated pancreatic carcinoma with large amount of 
necrotic tissue (B, asterisk) and sarcomatoid structure (100x). C and D: moderately well-differentiated glandular 
PDAC with tumor blood vessels in the periphery (C, asterisk) (200x). E-H: well-differentiated morphology of 
PDAC with abundant tumor stroma (arrows) (200x). E and F show PanIN lesions and tumors in KPC mice (E, 
arrow) in close proximity to duodenum (E, asterisk) and acinus cells of the pancreas (E, star). These triple 
mutant mice develop numerous PanIN lesions (F, asterisk). G and H show tumors of KPfC mice (200x), with 
PanINs (arrows) and overt adenocarcinoma (asterisk). 
 
* 
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Results 
44 
6.1.2 Collagen staining of tumor stroma 
Staining of collagen fibers in pancreatic carcinoma reveals tumor stroma. Panc02 tumors showed very 
little tumor stroma, whereas T110299 tumors exhibited areas with large amount of stroma within the 
tumor (Figure 6-2 A and B). Both, KPC and KPfC tumors were characterized by extensive stroma 
formation (Figure 6-2 C and D). 
 
 
Figure 6-2: Collagen staining of pancreatic tumors. 
Visualization of collagen fibers in tumor stroma was performed with Masson’s Trichrome. Collagen fibers are 
depicted in blue, nuclei in black, cytoplasma and erythrocytes in red. A: Orthotopic Panc02 tumors contain very 
little tumor stroma (100x). B: Orthotopic T110299 tumors show areas with large amounts of tumor stroma in the 
periphery as well as within the tumor (100x). C and D: Tumors from KPC and KPfC mice exhibit extensive 
stroma formation (200x). 
6.1.3 Differentiation of PDAC and PanIN lesions 
Precursor lesions leading to PDAC are called PanINs. These lesions are characterized by conversion of 
the duct epithelial cells to a columnar phenotype with mucin accumulation (Hingorani et al., 2003, 
Hingorani et al., 2005). To visualize PanINs in the different mouse models, Alcian blue staining was 
performed (Figure 6-3). PanIN lesions are graded into three different stages. The mucin content 
decreases with decreasing differentiation status. Formation of papillary architecture and luminal 
budding was observed, with loss of polarity and appearance of atypical nuclei. Differentiation of 
tumors is separated into three stages, from grade 1 well-differentiated to grade 3 poorly differentiated 
tumors. Panc02 tumors did not show any precursor lesions (Figure 6-3 A), resembling a grade 3 
tumor. T110299 tumors revealed glandular structure and stained weakly for mucin-containing PanIN-
like lesions with Alcian blue (Figure 6-3 B). Therefore theses tumors depicted grade 2 tumors. Tumors 
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from KPC mice showed strong Alcian blue staining; KPC tumors (Figure 6-3 C) demonstrated more 
mucin rich PanIN lesions than KPfC tumors, both resemble grade 1 tumors. 
 
 
Figure 6-3: Alcian blue staining reveals differentiation status of pancreatic carcinoma. 
Visualization of differentiation was performed with Alcian Blue staining. Mucin rich lesions are depicted in 
blue, cytoplasma in light red and nuclei in dark red. A: Orthotopic Panc02 tumors show differentiation of a grade 
3 tumor . B: Orthotopic tumors from T110299 cell line reveal weak mucin staining in some tumor areas, 
indicative of grade 2 tumors. C: Early stage PanIN rich tumors from KPC mice with a differentiation status of 
grade 1. D: PanIN rich tumors from KPfC tumors with low Alcian Blue staining, depict low differentiation of 
grade 1 tumors. All pictures were taken with a magnification of 200x.  
6.1.4 Tumor blood vessels 
The formation of tumor blood vessels gives rise to a better supply of oxygen and nutrients for the 
tumor. Blood vessels were examined with the help of the marker CD31, which stains endothelial cells. 
All tumors showed pronounced blood vessel formation in the periphery of the tumor (Figure 6-4 A-D). 
Differences between the tumor models became visible in the central tumor regions (c). In Panc02 
tumors blood vessels could be detected in the periphery (p), whereas tumor centers contained only few 
chaotic CD31 positive spots (Figure 6-4 A). Similarly, T110299 tumors showed formation of blood 
vessels in the tumor periphery, however in central tumor regions CD31 expression was sparse (Figure 
6-4 B). In sections of KPC tumors blood vessels were visible (Figure 6-4 C) at the tumor periphery, 
whereas in tumors of KPfC mice blood vessels occurred around adenocarcinoma structures (Figure 
6-4 D asterisk). In general, the architecture of the blood vessels in the tumors was chaotic compared to 
areas in the tumor periphery. In general, all PDAC model were hypovascular. 
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Figure 6-4: Tumor blood vessels in the periphery and center of pancreatic carcinoma. 
Tumor blood vessels were visualized via staining of the endothelial marker CD31 (polyclonal rabbit IgG, 
1:1000). Analyses were done for the periphery and central tumor regions. A: The periphery (p) of orthotopic 
Panc02 tumors are highly interspersed with blood vessels compared with central tumor parts (c) where almost no 
CD31 expression is detectable. B: Orthotopic T110299 tumors show abundant blood vessels at the tumor margin, 
whereas CD31 was almost absent in central regions. C and D: Tumors of KPC (C) and KPfC mice (D) 
demonstrate tumor blood vessel formation at the tumor border. Blood vessels were sparse in areas of 
adenocarcinoma (D, asterisk). All pictures were taken with a magnification of 200x.  
6.1.5 Infiltrating T cells 
T cell infiltrates of the orthotopic and spontaneous tumor models were investigated histologically by 
IHC. In orthotopic Panc02 tumors (Figure 6-5 A and B) and T110299 tumors (Figure 6-5 C and D) the 
infiltration with T cells was relatively high in comparison to the KPC and KPfC tumor models (Figure 
6-5 E-H). Most T cells accumulated at the border of the tumor (Figure 6-5 B, D, E and G). The central 
regions of Panc02 and T110299 tumors (Figure 6-5 A and C) also contained a brisk lymphocyte 
infiltrate. In central tumor parts of KPC mice the infiltration with T cells was very sparse (Figure 6-5 
F, G and H). In some areas T cell clustering in tumors could be recognized (Figure 6-5 H).  
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Figure 6-5: Infiltrating T cells in the periphery and center of pancreatic carcinoma. 
T cells were detected with an antibody against CD3 (monoclonal rabbit IgG [SP7], 1:250). Stars mark normal 
pancreatic tissue, arrowheads mark tumor regions. A and B: Orthotopic Panc02 tumors show clustering of T 
cells at the tumor border and a dense infiltration in the tumor center. C and D: Orthotopic T110299 tumors 
exhibit an accumulation of T cells at the tumor periphery but also in central regions. E and F: Tumors from KPC 
mice have sparse T cell infiltrates, but show T cells clustering at the tumor border. G and H: Tumors from KPfC 
mice are sparsely infiltrated with T cells in central regions (G) but show accumulation at the periphery of the 
tumor (G) and in some cases aggregation of T cells within the tumor was detectable (H). All pictures were taken 
with a magnification of 200x. 
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A quantification of T cells in the four tumor models was performed by counting CD3+ cells per 10 
high power fields (HPF). For this purpose tumors from KPC and KPfC mice were pooled. These 
tumors revealed a mean CD3+ count of about 52 cells per HPF whereas Panc02 tumors were 
significantly more infiltrated with T cells (mean CD3+ count 129) (Figure 6-6). Tumors from T110299 
cell line showed a very heterogeneous infiltration with T cells. The mean value of CD3+ T cells per 
HPF was 257. Both, T110299 and Panc02 tumors were significantly more densely infiltrated with T 
cells as tumors from KPC mice, whereas the difference between T110229 and Panc02 tumors was not 
statistically significant.  
 
Figure 6-6: Quantitative analysis of infiltrating T cells in pancreatic carcinoma. 
Tumors from KPC mice show the lowest infiltration with CD3+ T cells (mean value 52/HPF). In comparison, 
orthotopic tumors from Panc02 and T110299 cell lines were densely infiltrated with T cells with mean values of 
129 and 257/HPF, respectively. T110299 tumors were heterogeneously infiltrated by CD3+ T cells. On the 
contrary, Panc02 and GEMM tumors are more homogenously infiltrated with CD3+ T cells. Quantification of T 
cells was done by counting 10 HPF per tumor section. P value was calculated with student’s unpaired t test. 
Significant differences are marked with * = P<0.05, ** = P<0.005. GEMM = genetically engineered mouse 
model (KPC and KPfC). 
6.1.6 Galectin-1 and α-smooth muscle actin 
One of the immunosuppressive molecules investigated in this study is galectin-1. The expression of 
galectin-1 in murine pancreatic carcinoma models was investigated and compared with the expression 
of α-smooth muscle actin (α-SMA), a marker of fibroblasts and cells with fibroblastic origin like 
pancreatic stellate cells (PSCs). In the literature, PSCs located in tumor stroma have been described to 
express galectin-1 (Tang et al., 2011, Xue et al., 2011). As shown in Figure 6-7, all four tumor models 
express galectin-1 and α-SMA, but cellular distributions vary. Galectin-1 is expressed in the cytoplasm 
as well as in nuclei of stromal cells in KPC mice (Figure 6-7 G). α-SMA expression can be detected 
solely in the cytoplasm of elongated, fibroblast-like cells (Figure 6-7, H). As depicted in Figure 6-7 A 
and B Panc02 tumor cells have a strong expression of galectin-1 but α-SMA expression was not 
detectable, correlating with lack of tumor stroma. In T110299 tumors (Figure 6-7 C and D) the 
expression of both proteins was very distinctive whereas the tumors of KPC mice had a weaker 
expression (Figure 6-7 E and F). However, tumors of KPfC mice displayed a strong expression of 
galectin-1 and α-SMA (Figure 6-7 G and H).  
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Figure 6-7: Expression of galectin-1 and α-SMA in murine pancreatic carcinoma. 
Galectin-1 and α-SMA are expressed in the cytoplasm of stromal cells (PSC). Galectin-1was also expressed in 
nuclei of these types of cells. Galectin-1 was stained with a monoclonal antibody rat IgG2b [201002] (1:20.000). 
α-SMA staining was performed with a polyclonal rabbit IgG antibody (1:400). A and B: Orthotopic tumors from 
cell line Panc02 show strong expression of galectin-1 in tumor cells but no expression of α-SMA was detectable. 
C and D: Orthotopic T110299 tumors display strong expression of galectin-1 in tumor stroma, but not in 
carcinoma cells. E-H: The expression of both galectin-1 and α-SMA is weaker in KPC (E and F) tumors as 
compared to KPfC tumors (G and H). All pictures were taken with a magnification of 200x. 
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6.1.7 Indoleamine 2,3-dioxygenase 
Another immunosuppressive molecule, which was examined histologically, was indoleamine 2,3-
dioxygenase (IDO). As shown in Figure 6-8 this protein was expressed primarily in the cytoplasm of 
carcinoma cells. Acinus cells from healthy pancreatic tissue also displayed IDO expression (Figure 6-8 
C asterisks). Panc02 tumors (Figure 6-8 A) revealed a strong expression of IDO. Little IDO expression 
was detectable in cells located in the tumor stroma in any of the tumor models. Interestingly, PanIN 
lesions of KPC and KPfC mice revealed apical polarity of IDO expression (Figure 6-8 C and D). 
 
 
Figure 6-8: Indoleamine 2,3-dioxygenase expression in murine pancreatic carcinoma. 
IDO is primarily expressed in the cytoplasm of epithelial cells, cells with epithelial origin and acinus cells of the 
pancreas. IDO was stained with a polyclonal antibody rabbit IgG (1:50). A: Panc02 tumors show a distinct 
expression of IDO (200x). B: Tumors from T110299 cell line revealed expression of IDO in tumor cells 
(arrows). Tumor stroma, which consists of fibroblasts, fibroblast-like cells and collagen fibers, show less IDO 
expression (100x). C and D: Tumors from KPC and KPfC mice display IDO expression tumor cells and in 
PanIN lesions in an apical polarity (200x). 
6.1.8 Survival of mice bearing orthotopic Panc02 or T110299 tumors  
The murine pancreatic cancer cell lines Panc02 and T110299 were further characterized in vivo with 
regard to survival. Therefore, tumor cells were injected orthotopically into the head of the pancreas in 
C57BL/6 mice as it is described in chapter 5.4.3.1. Mice were euthanized when showing signs of 
distress or behavioral abnormalities. Both tumor models showed aggressive tumor biology. Mice with 
Panc02 tumors had a median survival of 31 days (n=6) whereas in mice with T110299 tumors the 
median survival was 23 days (n=7), however the difference was not significant (P=0.2598) (Figure 
6-9). 
* 
* 
* 
* 
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Figure 6-9: Survival of mice bearing orthotopic Panc02 and T110299 tumors. 
For survival, tumor cells of Panc02 (2*105 cells) and T110299 (4*105 cells) were injected orthotopically into the 
head of the pancreas of C57BL/6 mice. The median survival of mice with Panc02 tumors was 31 days (n=12), 
with T110299 tumors 23 days (n=7). Pooled data with statistical analysis from two independent experiments 
with 7 to 12 mice per group are depicted. 
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6.2 Immunotherapy with siRNA targeting galectin-1 in the Panc02 tumor model 
Therapeutic application of 5’ppp-modified siRNA (ppp-Gal-1) and unmodified siRNA (OH-Gal-1) 
targeting galectin-1 was one of the aims of this study. First, in vitro assays were performed to validate 
the expression of galectin-1 and intact RIG-I signaling in pancreatic cancer. In a second step, in vivo 
studies were conducted to assess the effect of OH-Gal-1 and ppp-Gal-1 in the Panc02 tumor model 
regarding influence on tumor growth and galectin-1 expression. In addition, the expression profiles of 
specific cytokines in the serum and status of immune cell activation were assessed.  
6.2.1 Murine Panc02 pancreatic carcinoma cells express functional RIG-I 
The first question that had to be answered was if pancreatic carcinoma cell lines express functional 
RIG-I as a prerequisite for successful treatment with bifunctional ppp-siRNA. RIG-I is a cytoplasmic 
receptor, which recognizes viral RNA with a 5’triphosphate end. RIG-I expression is regulated by type 
I IFNs. Initially, untreated, IFN-α or IFN-β treated Panc02 and T110299 cells were analyzed for RIG-I 
expression by qRT-PCR. Both cell lines displayed basal expression levels of RIG-I mRNA that were 
up-regulated upon stimulation with type I IFNs (Figure 6-10 A). Furthermore, treatment of Panc02 
cells with the RIG-I ligand ppp-RNA resulted in the secretion of CXCL10 and IFN-β as well as up-
regulation of MHC-I expression on the cell surface. In contrast, stimulation of T110299 cells with 
ppp-RNA induced lower levels of secreted CXCL10 and no induction of IFN-β and MHC-I could be 
detected (Figure 6-10 B-D). In line with intact RIG-I signaling, Panc02 cells phosphorylated the 
transcription factor IRF3 upon ppp-RNA stimulation. However, this was not observed for T110299 
cells, indicative of defective RIG-I signaling (Figure 6-10 E). Furthermore, ppp-RNA induced 
apoptosis in Panc02 tumor cells, as assessed by Annexin V/PI staining, whereas viability of T110299 
cells was not affected (Figure 6-10 F). 
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Figure 6-10: Murine Panc02 but not T110299 PDAC cells express functional RIG-I. 
A: Panc02 and T110299 cells were cultured in the absence or presence of 1000 IU/ml IFN-α or IFN-β for 12 h. 
RIG-I expression was determined by qRT-PCR and normalized to HPRT.  B and C: Panc02 and T110299 cells 
were stimulated with 500 ng/ml OH-RNA or ppp-RNA for 24 h or left untreated. CXCL10 secretion was 
analyzed by ELISA. MHC-I expression was determined by flow cytometry and depicted as mean fluorescence 
intensity (MFI). D: Tumor cells were stimulated with 500 ng/ml OH-RNA or ppp-RNA for 12 h or left 
untreated. IFN-β mRNA was determined by qRT-PCR. E: Phosphorylation of IRF3 in Panc02 and T110299 
cells stimulated with OH-RNA or ppp-RNA for 2 h was assessed by Western Blot analysis. F: Tumor cell 
viability was measured after treatment with 3 µg/ml OH-RNA or ppp-RNA for 48 h by Annexin V/PI staining. 
Viable cells were defined as Annexin V-PI- cells. Graphs represent one of three independent experiments. 
Asterisks indicate * P < 0.05. 
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To confirm that ppp-RNA-induced up-regulation of CXCL10 and MHC-I expression is mediated by 
the RIG-I signaling pathway, RNAi was used to silence RIG-I expression before stimulation. Panc02 
cells were transfected with siRNA targeting RIG-I or scrambled siRNA. After 24 h tumor cells were 
stimulated with OH-RNA or ppp-RNA. Up-regulation of MHC-I expression and CXCL10 secretion 
were analyzed by FACS (Figure 6-11 A) and ELISA (Figure 6-11 B), respectively. As expected, 
silencing of RIG-I expression abolished both MHC-I up-regulation and CXCL10 secretion induced by 
ppp-RNA. 
 
Figure 6-11: ppp-RNA-induced up-regulation of MHC-I expression and CXCL10 secretion is mediated by 
RIG-I. 
Panc02 tumor cells were transfected with 500 ng/ml siRNA targeting RIG-I or scrambled siRNA. After 24 h 
cells were stimulated with 500 ng/ml of indicated RNAs. A: Expression of MHC-I on Panc02 tumor cells was 
determined by flow cytometry. B: CXCL10 levels in tumor supernatant were measured by ELISA. 
Representative data of three independent experiments are shown. Bars represent mean + SD from duplicates. 
Significant differences were analyzed by unpaired student’s t-test. Asterisks indicate * P < 0.05. 
6.2.2 In vitro actions of unmodified and 5’ppp-modified siRNA targeting galectin-1 
The novel ppp-siRNA technology allows combining RIG-I activation with RNAi-mediated gene 
silencing in one molecule. Galectin-1 targeting siRNA (OH-Gal-1) was selected and the corresponding 
ppp-siRNA (ppp-Gal-1) was generated by in vitro transcription using a DNA template of the same 
sequence containing the T7 RNA polymerase promoter sequence. To verify the knockdown efficiency 
of both unmodified OH-Gal-1 as well as 5’ppp-modified ppp-Gal-1, qRT-PCR analysis was 
performed. As shown in Figure 6-12 A OH-Gal-1 induced a significant knockdown of galectin-1 
mRNA expression of 80% and 50% in Panc02 and T110299 cells, respectively. In Panc02 cells 
galectin-1 silencing with ppp-Gal-1 was not as efficient as with OH-Gal-1 (knockdown efficacy 50%). 
In contrast, in T110299 cells the knockdown of galectin-1 was similarly efficient for both ppp-
modified and unmodified siRNA. Treatment with ppp-RNA and ppp-Gal-1 influenced cell 
morphology from spindle-shaped towards round-shaped cells, indicative of apoptosis induction 
(Figure 6-12 B). 
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Figure 6-12: Silencing of galectin-1 expression in Panc02 and T110299 cells with unmodified and 5’ppp-
modified siRNA. 
A: Panc02 and T110299 cells were treated twice with 500 ng/ml OH-Gal-1 or ppp-Gal-1 for 12 h. Expression of 
Gal-1 mRNA was determined by qRT-PCR and is depicted as relative expression compared to untreated cells. 
Representative data of three independent experiments are depicted. Asterisks indicate P < 0.05. B: Panc02 cells 
were treated once with 500 ng/ml OH-Gal-1 or ppp-Gal-1 for 24 h. Galectin-1 immunofluorescence staining was 
performed with a primary mouse polyclonal antibody rabbit IgG (1:100) against Gal-1 and a secondary anti-
rabbit antibody AF488 (1:100). Nuclei were counterstained with Hoechst (1:200). 
 
Next, activation of RIG-I by the bifunctional ppp-Gal-1 molecule was validated. 24 h after stimulation 
with OH-Gal-1 or ppp-Gal-1, Panc02 and T110299 cells were analyzed with respect to CXCL10 
secretion and MHC-I expression. In both cell lines transfection with OH-Gal-1 or scrambled OH-RNA 
induced no CXCL10 secretion (Figure 6-13 A). In contrast, stimulation with ppp-RNA (irrelevant 
siRNA sequence) and ppp-Gal-1 resulted in CXCL10 secretion in both cell lines. As observed before, 
CXCL10 levels were significantly higher in Panc02 cells compared to T110299 cells (Figure 6-13 A). 
Moreover, ppp-Gal-1 induced similar levels of MHC-I and IFN-β expression as well as apoptosis as 
control ppp-RNA in Panc02 cells. Again, T110299 cells showed no signs of RIG-I activation (Figure 
6-13 B-D). 
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Figure 6-13: 5’ppp-modified siRNA targeting galectin-1 combines gene silencing with RIG-I signaling. 
A and B: Panc02 and T110299 cells were treated with 500 ng/ml OH-Gal-1 or ppp-Gal-1 for 24 h. CXCL10 
secretion was measured by ELISA and MHC-I expression was analyzed by flow cytometry. C: Expression levels 
of IFN-β mRNA were determined by qRT-PCR after stimulation of tumor cells with 3 µg/ml of indicated RNA 
for 12 h and normalized to HPRT. D: FACS analysis of cell viability by AnnexinV/PI staining 48 h after 
transfection with 3 µg/ml of RNAs. Representative data of three independent experiments are depicted. Asterisks 
indicate P < 0.05. 
6.2.3 In vivo actions of unmodified and 5’ppp-modified siRNA targeting galectin-1 
Based on the in vitro studies demonstrating intact RIG-I signaling only in Panc02 cells, in vivo studies 
were performed in the Panc02 tumor model. In first experiments, Panc02 cells were injected 
subcutaneously in the flank of wild-type C57BL/6 mice. Serum was collected weekly over six weeks 
to determine galectin-1 levels during progressive tumor growth. As shown in Figure 6-14, galectin-1 
serum levels significantly correlated with tumor size (p<0.005). 
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Figure 6-14: Galectin-1 serum levels in mice with Panc02 tumors correlate with tumor size. 
Panc02 cancer cells were injected subcutaneously in the right flank of C57BL/6 mice (n=5). Tumor size was 
measured every other day. Serum was collected once weekly and galectin-1 levels were determined by ELISA. 
Correlation was significant (Pearson r = 0.6571). 
 
Next, tumor tissue and sera of mice treated with OH-Gal-1 were analyzed in regards to galectin-1 
levels. Mice with orthotopic Panc02 tumors showed similar galectin-1 mRNA expression levels after 
treatment with 50 µg of scrambled siRNA or OH-Gal-1 repeated three times every 48 h (Figure 6-15 
A). No significant galectin-1 reduction in tumor tissue could be achieved by systemic OH-Gal-1 
application via the tail vein. Galectin-1 serum levels increased significantly in mice with Panc02 
tumors (Figure 6-15 B). Treatment with OH-RNA had no influence on galectin-1 serum levels. OH-
Gal-1 treated mice showed reduced galectin-1 serum levels as compared to untreated or OH-RNA 
treated mice, however this reduction missed statistical significance (2-3 mice per group). 
 
Figure 6-15: Galectin-1 mRNA levels in tumors and serum protein levels in mice with orthotopic Panc02 
tumors after treatment with siRNA targeting galectin-1. 
Panc02 cells were injected orthotopically in the pancreas of wild-type C57BL/6 mice. Animals were treated 
three times every 48 h with 50 µg of the indicated RNAs complexed with in vivo jetPEI via the tail vein. Mice 
were sacrificed 24 h after the last injection and serum and tumor tissue were collected. A: Galectin-1 mRNA 
expression in tumor tissue was analyzed by qRT-PCR. B: Galectin-1 serum levels were measured by ELISA. 
Data from two to three mice per group are represented as mean +/- SEM. 
 
Next, the therapeutic efficacy of treatment with OH-Gal-1 and ppp-Gal-1 was investigated in the 
subcutaneous and orthotopic Panc02 tumor model (Figure 6-17). Treatment started at day 10 after 
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tumor induction and was repeated twice weekly over three weeks with 50 µg siRNA via the tail vein. 
Systemic treatment with ppp-Gal-1 led to enhanced serum levels of IFN-α, CXCL10 and TNF-α 
(Figure 6-16 A). In addition, splenic CD4+ and CD8+ T cell, B cells, NK cells and NKT cells up-
regulated CD69 expression, indicative of systemic RIG-I activation (Figure 6-16 B).  
 
Figure 6-16: Systemic treatment of Panc02 tumor-bearing mice with unmodified and modified 5’ppp-
RNA silencing galectin-1. 
Mice with subcutaneous Panc02 tumors were treated with RNA ten days after tumor induction. Mice were 
treated twice weekly over three weeks with 50 µg of indicated RNA via the tail vein. Serum was analyzed 6 h 
post third RNA injection. A: Levels of IFN-α, CXCL10 and TNF-α were analyzed by ELISA. B: Activation 
status of peripheral lymphocytes was determined by staining of CD69 and analyzed by flow cytometry. Pooled 
data from 4 to 5 mice per group are represented as mean + SEM. P-values < 0.05 were considered significant. 
 
Results 
59 
In the subcutaneous tumor model all mice without treatment or treated with OH-RNA had to be 
sacrificed by day 37 due to progressive tumor growth. At this time point, mice treated with control 
ppp-RNA or OH-Gal-1 showed a significantly delayed tumor growth (52% size reduction compared to 
untreated mice). Mice in the ppp-Gal-1 group showed the best tumor control (64% size reduction 
compared to untreated mice). In the orthotopic tumor model, all mice without treatment or treated with 
scrambled OH-RNA had to be sacrificed within 40 days after tumor induction caused by progressive 
tumor growth (median survival 33 and 29 days, respectively). Mice treated with OH-Gal-1 showed no 
significantly prolonged survival (median survival 35 days), whereas treatment with control ppp-RNA 
(same sequence as scrambled OH-RNA) resulted in a significantly extended survival (median survival 
41 days). Mice treated with ppp-Gal-1 showed the best survival (median survival 49 days). Of note, 20 
% of mice treated with ppp-Gal-1 rejected their tumor and stayed tumor free for an observation period 
of 100 days as compared to 8 % of mice treated with ppp-RNA and 0 % in the other therapy groups.  
 
Figure 6-17: Survival of subcutaneous and orthotopic Panc02 tumor-bearing mice after treatment with 
unmodified and modified 5’ppp-RNA silencing galectin-1. 
Mice with subcutaneous or orthotopic Panc02 tumors were treated with RNA ten days after tumor induction. 
Mice were treated twice weekly over three weeks with 50 µg of indicated RNA via the tail vein. A: Tumor size 
of subcutaneous tumors was measured every three days by caliper (n=4-5/group). B: Survival in the orthotopic 
model was monitored. Experiments were terminated after 100 days. Median survival of untreated mice: 33 days 
(n=12); OH-RNA: 29 days (n=7); ppp-RNA: 41 days (n=13); OH-Gal-1: 35 days (n=5); ppp-Gal-1: 49 days 
(n=5). Pooled data with statistical analysis from two independent experiments with 4-5 mice per group in the 
subcutaneous and 5 to 13 mice per group in the orthotopic model are depicted. P-values for statistical 
comparisons are shown in the graph. 
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6.3 Tumor immune escape mechanisms in pancreatic ductal adenocarcinoma 
T cells play an important role in tumor control by the immune system. Lymphocyte infiltrations in 
pancreatic tumors represent a good prognostic factor, however usually only few T cells can be found 
in the tumors. In addition, these T cells are often dysfunctional (Garbe et al., 2006, Mukherjee et al., 
2001). Identifying the mechanisms leading to tumor immune escape in pancreatic cancer are important 
for the development of effective immunotherapeutic strategies. Here, general mechanisms like the 
influence of the tumor cells on T cell proliferation and degranulation were investigated and possible 
immunosuppressive molecules like galectin-1, TGF-β and IDO were analyzed with respect to their 
expression level in tumor cells and contribution to T cell inhibition. 
6.3.1 Soluble factor(s) in tumor supernatant inhibit T cell proliferation 
As an initial experiment T cell proliferation induced by CD3 and CD28 ligation via mAb coated beads 
in the absence or presence of PDAC cell supernatant was assessed. Therefore, primary isolated T cells 
from mouse spleen were labeled with CFSE, stimulated with beads and incubated with tumor 
supernatant for 72 h. Proliferation of CD4+ and CD8+ T cells was analyzed by flow cytometry. The 
tumor supernatant was generated by plating 5*105 tumor cells per well in a 6-well plate with 2 ml T 
cell medium for 24 h. As shown in Figure 6-18, supernatant of both Panc02 and T110299 cells 
inhibited the proliferation of both CD4+ and CD8+ T cells in a dose-dependent manner. This inhibition 
was very efficient; as little as 0.75% of tumor supernatant decreased T cell proliferation by 
approximately 50% (Figure 6-18). The inhibitory effect was more pronounced for CD4+ T helper cells. 
However, 25% of supernatant almost completely abolished proliferation of both T cell types. 
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Figure 6-18: Inhibition of T cell proliferation by tumor supernatant from murine PDAC cell lines. 
Primary isolated untouched T cells from mouse spleen were labeled with 2.5 µM CFSE, stimulated with anti-
CD3/CD28 Dynabeads and incubated in the absence or presence with indicated percentages of tumor supernatant 
(Tumor-SN) for 72 h. T cell proliferation was analyzed by flow cytometry. Proliferation of T cells in medium 
without tumor supernatant was normalized to 100%. Representative data of three independent experiments are 
shown. Bars represent mean +/- SD from duplicates.  
 
The inhibitory effect on T cell proliferation was next assessed using antigen-specific T cells. Splenic 
CD8+ T cells were isolated from OT-1 mice and labeled with CFSE. These T cells are transgenic for a 
T cell receptor recognizing the ovalbumin epitope SIINFEKL in the context of MHC-I molecules. To 
stimulate the T cells SIINFEKL-pulsed DCs were added to the T cell culture. Proliferation of CD8+ T 
cells was analyzed by flow cytometry. T cell proliferation of OT-1 CD8+ T cells was significantly 
inhibited by tumor supernatant from both Panc02 and T110299 cells (Figure 6-19). 
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Figure 6-19: Suppression of OT-1 T cell proliferation by tumor supernatant. 
Primary isolated untouched CD8+ T cells from OT-1 mouse spleen were labeled with 2.5 µM CFSE, stimulated 
with SIINFEKL-pulsed DCs and incubated in the absence or presence of tumor supernatant (Tumor-SN) for 72 
h. T cell proliferation was analyzed by flow cytometry. T cell proliferation in the absence of tumor supernatant 
was normalized to 100%. Representative data of three independent experiments are shown. Bars represent mean 
+/- SD from duplicates. Significant differences were analyzed by one-way ANOVA including Bonferroni 
correction. P-values < 0.05 were considered significant.  
6.3.2 Tumor supernatant induces T cell apoptosis 
To address the question whether tumor supernatants induces T cell apoptosis, T cells were incubated 
with 6.25% tumor supernatant for 72 h in the presence of T cell stimulator beads and analyzed by flow 
cytometry using the Annexin V/PI assay. As depicted in Figure 6-20 A, cell viability of unstimulated 
T cells (no beads) and T cells cultured with tumor supernatant of Panc02 and T110299 cells decreased 
significantly up to 80%. In addition, T cells cultured in the presence of tumor supernatant significantly 
up-regulated expression of the death receptor Fas (CD95) (Figure 6-20 B). Interestingly, T cells that 
were first stimulated with beads for 24 or 48 h before addition of tumor supernatant were not affected 
in their proliferative response and did not undergo apoptosis (Figure 6-20 C). This indicates that 
soluble factor(s) present in the tumor supernatant of PDAC cells inhibit proliferation only of naïve, not 
previously activated T cells. 
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Figure 6-20: T cell apoptosis induced by tumor supernatant of murine PDAC cells. 
A: Primary untouched T cells (white bars CD4+, gray bars CD8+) from mouse spleen were stimulated with anti-
CD3/CD28 Dynabeads and incubated in the absence or presence of 6.25% tumor supernatant for 72 h. Annexin 
V/PI staining was analyzed by flow cytometry. Viability was defined as Annexin V-/PI- cell population and 
normalized to 100% of stimulated T cells in the absence of supernatant. B: Stimulated T cells were cultured in 
the absence or presence of 6.25% tumor supernatant for 72 h. Fas (CD95) expression was analyzed by flow 
cytometry. C: T cells were stimulated with anti-CD3/CD28 Dynabeads and cultured in the absence or presence 
of 25% tumor supernatant. (1) 48 h preincubation with T cell medium followed by 24 h incubation with tumor 
supernatant. (2) 24 h preincubation with T cell medium followed by 48 h incubation with tumor supernatant and 
(3) 72 h incubation with tumor supernatant. Representative data of three independent experiments are shown. 
Bars represent mean +/- SD from duplicates. Significant differences were analyzed by one-way ANOVA 
including Bonferroni correction. P-values < 0.05 were considered significant.  
6.3.3 Soluble factors do not impair cytotoxic T cell degranulation 
An important function of cytotoxic T cells is degranulation with release of perforin and granzyme B to 
induce target cell killing. During this process intracellular granules filled with perforin and granzyme 
B fuse with the cell membrane of T cells for secretion into the extracellular space. Perforin generates 
pores in the cell membrane of target cells while granzyme B triggers apoptotic processes. On the inner 
membrane of these granules the molecules CD107a and CD107b, also referred as LAMP-1 and 
LAMP-2, reach the surface and can be bound by antibodies as indirect measurement of degranulation. 
To assess whether tumor supernatant affects T cell degranulation, primary cytotoxic T cells isolated 
from OT-1 mice were stimulated with SIINFEKL-pulsed DCs and incubated with 6.25% tumor 
supernatant for 5 h. As shown in Figure 6-21, the degranulation of cytotoxic T cells was not reduced 
by soluble factors in PDAC supernatants. 
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Figure 6-21: Soluble factors do not impair cytotoxic T cell degranulation. 
Primary isolated untouched CD8+ T cells from OT-1 mouse spleen were incubated with fluorochrome-labeled 
CD107a/b antibodies in the absence or presence of tumor supernatant (6.25%) for 5 h. T cell stimulation was 
done by SIINFEKL-pulsed antigen presenting cells (APC-SIINFEKL). CD107 expression was analyzed by flow 
cytometry. Representative data of three independent experiments are shown. Bars represent mean +/- SD from 
duplicates. Significant differences were analyzed by one-way ANOVA including Bonferroni correction. P-values 
< 0.05 were considered significant.  
6.3.4 T cell inhibition is mediated by a tumor-derived soluble protein 
Next, the question was addressed how PDAC cells mediated T-cell inhibition. One important pathway 
in T cell function that is accountable for T cell homeostasis and peripheral tolerance is the PD-1/PD-
L1 axis. PD-1 is upregulated on T cells when they are activated to regulate T cell responses (Chen and 
Flies, 2013). PD-L1, the ligand for PD-1, is normally expressed on antigen presenting cells, but can 
also be expressed on tumor cells (Okudaira et al., 2009, Nomi et al., 2007, Dong et al., 2002, Butte et 
al., 2007). There is also evidence that PD-L1 can be released by tumor cells (Frigola et al., 2012, 
Frigola et al., 2011). Therefore, it was investigated if soluble PD-L1 could be responsible for T cell 
inhibition in tumor supernatants. Western blot analysis of tumor supernatants revealed that both cell 
lines secrete PD-L1 (Figure 6-22 A). However, blocking PD-1 or B7-1, another receptor for PD-L1, 
on T cells using monoclonal antibodies did not restore T cell proliferation (Figure 6-22 B and C), 
ruling out a major contribution of this pathway in our experimental setting. 
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Figure 6-22: Murine PDAC cells secrete PD-L1, but the PD-1/PD-L1 axis is not responsible for tumor 
supernatant-induced T cell inhibition. 
A: Western Blot analysis of PD-L1 from tumor supernatants of Panc02 and T110299 cell lines using a CD274 
mAb (clone MIH5, 1:1000). B: Effect of PD-1 blocking on primary T cells with anti-CD279 mAb (clone J43, 5 
µg/ml) in a T cell proliferation assay. C: Effect of blocking B7-1 on primary T cells with anti-CD80 mAb (clone 
16-10A1, 5 µg/ml). Representative data of three independent experiments are shown. Bars represent mean +/- 
SD from duplicates. 
 
To gain further insight into the possible mechanisms leading to T cell suppression, 50 IU/ml of IL-2 
were added to the T cell culture as an attempt to rescue T cell proliferation. Moreover, benzonase, a 
nuclease degrading immunosuppressive nucleotides, was added. Neither IL-2 nor benzonase rescued T 
cell suppression mediated by tumor cell supernatants (Figure 6-23 A). However, heating of the tumor 
supernatant to 95°C for 10 min resulted in a complete restoring of T cell proliferation (Figure 6-23 A). 
Instability to heating argues that the immunosuppressive factor may be a protein that was denatured by 
boiling. To verify if a tumor-derived protein is responsible for T cell inhibition, tumor supernatant was 
treated with Proteinase K before adding to the T cells. Proteinase K treatment lead to a significant 
increase in T cell proliferation (Figure 6-23 B), indicating that a tumor-derived soluble protein 
mediates T cell inhibition. 
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Figure 6-23: T cell inhibition is mediated by a tumor-derived protein, whereas nucleotides or 
prostaglandins are dispensable.  
Freshly isolated splenic T cells were labeled with CFSE and incubated in the absence or presence of CD3/CD28 
Dynabeads for 72 h and T cell proliferation was analyzed by flow cytometry. A: Tumor supernatants (6.25%) of 
Panc02 and T110299 cells were treated either with 50 IU/ml IL-2 or 50 IU/ml benzonase (nuclease) or boiled for 
10 min before adding to T cells. B: Tumor supernatant was treated with Proteinase K beads (5 mg/ml) for 2 h. 
6.25% tumor supernatant was added to T cells. C: Tumor cells were treated either with 10 µM SC-560, an 
inhibitor of COX1 (iCox1), or 20 µM Celecoxibe, an inhibitor of COX2 (iCox2), for 24 h. 25% supernatant of 
treated or untreated tumor cells was used for T cell proliferation assay. D: Murine T cells were incubated with 
tumor supernatant from human pancreatic cancer cells (PANC-1 and IMIM-PC-1). Representative data of three 
independent experiments are shown. Bars represent mean +/- SD from duplicates. Significant differences were 
analyzed by one-way ANOVA including Bonferroni correction. P-values < 0.05 were considered significant. 
 
Prostaglandins are known for their immune regulatory role via inhibiting T cell function (Loose and 
Van de Wiele, 2009). Prostanoids are generated by the enzymes cyclooxygenase 1 and 2 (COX1 and 
2). To analyze if tumor-derived prostanoids play a role in T cell inhibition, PDAC cells were 
pretreated with the COX1 inhibitor SC-560 or COX2 inhibitor Celecoxibe for 24 h and supernatants 
collected. As shown in Figure 6-23 C, COX inhibition did not affect T cell proliferation.  
 
To gain further information regarding the nature of the inhibitory factor, it was assessed whether the 
factor is also produced by human PDAC cells and if the factor is species cross-reactive. To this end, 
supernatant from human IMIM-PC1 and PANC-1 cell lines were collected and added to murine T cell 
proliferation assays (Figure 6-23 D). These assays could clearly show that human PDAC cells are also 
capable of suppressing proliferation of murine T cells.  
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Taken together, PDAC cells produce a T cell proliferation suppressing factor, that is a) soluble, b) 
heat-labile, c) likely a protein (prostanoids and nucleotides were ruled out) and d) capable of cross-
reacting between mice and humans. Thus, likely candidates that were investigated in subsequent 
studies were a) TGF-β which shares close homology in different species, b) galectin-1 which is 
produced in high levels by PDAC cells, and c) IDO which produces tryptophan catabolites leading to 
T cell apoptosis in both human and murine T cells. 
6.3.5 T cell inhibition is not mediated by galectin-1 
A molecule with T cell inhibitory function, which can be produced by tumor cells, is galectin-1. 
Therefore, the expression of galectin-1 was analyzed in cell lysates as well as supernatants of Panc02 
and T110299 cells by ELISA. As shown in Figure 6-24, galectin-1 was expressed in high levels by 
PDAC cells. Moreover, galectin-1 could be found in tumor supernatants, although at significantly 
lower levels.  
 
Figure 6-24: Galectin-1 content in cell lysate and supernatant of murine PDAC cells. 
Panc02 and T110299 cells where plated in a 96-well plate for 24 h. Supernatant was collected and pelleted cells 
where lysed with 60 µl lysis buffer for 10 min on ice. Galectin-1 content was measured by ELISA. 
Representative data of three independent experiments are shown. Bars represent mean + SD from duplicates. 
Significant differences were analyzed by one-way ANOVA including Bonferroni correction. P-values < 0.05 
were considered significant. 
 
To assess the possible contribution of secreted galectin-1 on T cell inhibition, T110299 cells were 
treated with specific siRNA targeting Gal-1 and supernatants collected. Although galectin-1 silencing 
resulted in 50% reduced mRNA expression levels (Figure 6-12 A), this had no effect on T cell 
inhibition mediated by T110299 cells (Figure 6-25). 
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Figure 6-25: T cell inhibition is not affected by siRNA based silencing of galectin-1 in T110299 cells. 
T110299 cells were plated in a 96-well plate (4*104 cell per well) and galectin-1 expression was silenced with 
500 ng/ml OH-Gal-1. After 24 h 50% of tumor supernatant (Tumor-SN) was used for T cell proliferation assay. 
CFSE labeled T cells were incubated in the absence or presence of CD3/CD28 Dynabeads with or without tumor 
supernatant for 72 h and analyzed by flow cytometry. Representative data of three independent experiments are 
shown. Bars represent mean + SD from duplicates. Significant differences were analyzed by one-way ANOVA 
including Bonferroni correction. P-values < 0.05 were considered significant. 
 
To exclude, that RNAi-mediated galectin-1 silencing was insufficient, two different inhibitors of 
galectin-1 were used: β-lactose, a natural inhibitor of galectin-1, and Thiodigalactoside (TDG), a 
synthetic and metabolically stable inhibitor (Ito et al., 2011). Treatment with 50 mM β-lactose in 25% 
tumor supernatant had no effect on T cell inhibition and apoptosis, respectively (Figure 6-26 A and B). 
Similarly, treatment with TDG demonstrated that galectin-1 was not involved in T cell inhibition 
(Figure 6-26 C) as CD4+ and CD8+ T cells showed the same proliferation rate compared to untreated 
or sucrose (control) treated tumor supernatant, respectively. 
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Figure 6-26: Galectin-1 inhibition does not restore inhibition of T cell proliferation. 
Primary untouched T cells were incubated in the absence or presence of CD3/CD28 Dynabeads and proliferation 
was analyzed by flow cytometry. Inhibitors of galectin-1 were added to tumor supernatants (25%) of Panc02 and 
T110299 cells. A: T cell proliferation assay with 50 mM β-lactose in tumor supernatant. B: T cell viability was 
determined by Annexin V/PI staining after 72 h. Viable cells were defined as Annexin V-/PI-. C: T cells were 
incubated with 12.5% tumor supernatant of Panc02 and T110299 cells, which were treated with 10 mM 
Thiodigalactoside (TDG) or 10 mM sucrose as negative control for 72 h in a T cell proliferation assay. 
Representative data of three independent experiments are shown. Bars represent mean +/- SD from duplicates. 
Significant differences were analyzed by one-way ANOVA including Bonferroni correction. P-values < 0.05 
were considered significant. 
6.3.6 Blocking TGF-β receptor signalling partially restores T cell proliferation 
Panc02 tumor cells have previously been shown to secrete TGF-β into tumor supernatant and serum 
levels of TGF-β were progressively elevated in Panc02 tumor-bearing mice (Ellermeier et al., 2013). 
As TGF-β is a potent immune suppressive molecule and is cross-reactive between different species 
due to its highly conserved sequence, the role of this cytokine in regards to tumor supernatant-
mediated T cell inhibition was analyzed. Initially, silencing of TGF-β1 was performed using siRNA 
technology. Panc02 cells were treated twice with 500 ng/ml siRNA targeting TGF-β1 and 24 h after 
the second transfection the tumor supernatant (6.25%) was used for T cell proliferation assays (Figure 
6-27). Silencing of TGF-β1 did not restore T cell proliferation, but silencing efficacy was only partly 
effective with reduction of TGF-β1 mRNA between 50-70% (data not shown). Another problem of this 
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approach might be that the siRNA targets only a single TGF-β isoform, but not two other isoforms, 
TGF-β2 and TGF-β3.  
 
Figure 6-27: T cell inhibition is not influenced by siRNA based silencing of TFG-β1. 
Panc02 cells were incubated with siRNAs (2 x 500 ng/ml) with or without silencing activity against TGF-β for 
24 h or left untreated. 6.25% tumor supernatant (Tumor-SN) was used in T cell proliferation assay and T cell 
proliferation was analyzed after 72 h by flow cytometry. Representative data of three independent experiments 
are shown. Bars represent mean +/- SD from duplicates. Significant differences were analyzed by one-way 
ANOVA including Bonferroni correction. P-values < 0.05 were considered significant. 
 
Taking these considerations into account, the competitive TGF-β receptor 1 kinase inhibitor SD-208 
was used for subsequent experiments. T cells were incubated with 10 µM SD-208 for 2 h before 
addition of 6.25% tumor supernatant for further 72 h. As depicted in Figure 6-28, treatment with SD-
208 significantly restored T cell proliferation in cultures exposed to either Panc02 or T110299 
supernatant. Interestingly, the CD8+ T cell population was more affected than the CD4+ T cell 
population. While T cells exposed to supernatant of Panc02 cells regained 50% proliferation capacity 
with respect to CD8+ T cells and 20% for CD4+ T cells, the T cells exposed to T110299 tumor 
supernatant displayed approx. 70% recovered proliferation for CD8+ T cells and 30% for CD4+ T cells.  
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Figure 6-28: Inhibition of TGF-β-receptor signaling partially restores T cell proliferation. 
Primarily CFSE labeled T cells from mouse spleen were stimulated with anti-CD3/CD28 Dynabeads and 
incubated in the absence or presence of 10 µM of the TGF-β receptor 1 kinase inhibitor SD-208 for 2 h. DMSO 
served as vehicle control. Subsequently, 6.25% tumor supernatant (Tumor-SN) was added to the T cells for 
additional 72 h. Analysis of proliferation was performed by flow cytometry. Representative data of three 
independent experiments are shown. Bars represent mean +/- SD from duplicates. Significant differences were 
analyzed by one-way ANOVA including Bonferroni correction. P-values < 0.05 were considered significant. 
6.3.7 Blocking IDO activity partially restores T cell proliferation 
Although TGF-β signaling in T cells seems to be important for tumor-mediated inhibition of T cell 
proliferation, there are probably additional factors impacting T cell function, as evidenced by only 
partial recovery of T cell proliferation by SD-208.  
 
Several studies have shown that IDO is highly expressed in pancreatic cancer (Lee et al., 2002, 
Johnson et al., 2009, Katz et al., 2008). To analyze if IDO could be an additional factor that negatively 
influences T cell proliferation in our experimental setting, Panc02 and T110299 cells were treated with 
the IDO inhibitor D-1-methyltryptophan (D-1-MT) before the supernatant was collected and added to 
T cells. As shown in Figure 6-29 A, T cells exposed to supernatant from D-1-MT treated Panc02 cells 
showed a significant increase of CD8+ T cell proliferation. In addition, inhibition of IDO revealed a 
trend for restoring T cell proliferation for T110299 cells, however this was statistically not significant 
(Figure 6-29 A). Interestingly, T cell proliferation could be further recovered when D-1-MT was 
added to the T cells together with the tumor supernatant (Figure 6-29 B). In this case, T cells regained 
approx. 90% proliferation capacity with respect to the CD8+ cells and 80% for the CD4+ cells for both 
PDAC cell lines, respectively. In addition, the blockade of IDO also protected T cells from undergoing 
apoptosis. T cells exposed to Panc02 supernatant showed significantly increased cell viability when 
treated with D-1-MT (Figure 6-29 C). D-1-MT treatment also increased T cell viability after exposure 
to T110299 supernatant. However, this effect was not statistically significant. Interestingly, T cells 
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upregulated expression of the death receptor Fas (CD95) after exposure to tumor supernatant (Figure 
6-20 B). Of note, IDO inhibition by D-1-MT decreased Fas expression (Figure 6-29 D). 
 
Figure 6-29: Inhibition of IDO rescues T cell from inhibition by PDAC cells. 
A: Panc02 and T110299 cells were treated with the IDO inhibitor D-1-MT (2 mM) for 24 h. Afterwards, tumor 
supernatant (SN) was used for T cell proliferation assays. B: D-1-MT was added to T cells in a T cell 
proliferation assay together with 6.25% SN of Panc02 and T110299 cells. C: Cell viability of T cells was 
measured by Annexin V/PI staining 72 h after stimulation with CD3/CD28 beads in the absence or presence of 
6.25% tumor SN and D-1-MT, respectively. D: T cell CD95 expression was measured 72 h after stimulation 
with CD3/CD28 beads in the absence or presence of 6.25% tumor SN and D-1-MT, respectively. Representative 
data of three independent experiments are shown. Bars represent mean +/- SD from duplicates. Significant 
differences were analyzed by one-way ANOVA including Bonferroni correction. P-values < 0.05 were 
considered significant. 
 
These surprising results indicate that a factor in the tumor supernatant of Panc02 and T110299 cells 
induces IDO expression in T cells, which finally leads to tryptophan depletion and the production of 
kynurenine. Kynurenine are products of tryptophan metabolism produced by IDO, which inhibit 
protein biosynthesis and induce T cell apoptosis. To assess whether tumor supernatants of Panc02 and 
T110299 cells increase IDO expression in T cells, we performed qRT-PCR analysis. As shown in 
Figure 6-30, IFN-γ, a well-known stimulus mediating IDO up-regulation in tumor cells and antigen-
presenting cells (Johnson et al.), induced to some extent IDO mRNA expression in CD4+ T cells, but 
not CD8+ T cells. In contrast, exposure to tumor supernatants induced pronounced up-regulation of 
IDO mRNA expression in both CD4+ as well as CD8+ T cells. T cell stimulation via CD3 and CD28 
alone had no influence on IDO expression. These results indicate that a so far unidentified factor 
Results 
73 
secreted by PDAC cells potently induces IDO expression in T cells, which might contribute to tumor-
mediated immunosuppression in the tumor micromilieu.  
 
Figure 6-30: Induction of IDO mRNA expression in T cells after exposure to tumor supernatant from 
Panc02 and T110299 cells. 
Freshly isolated CD4+ and CD8+ T cells from mouse spleen were incubated with or without tumor supernatant 
(25%) from Panc02 or T110299 cells or with IFN-γ (2000 U/ml) for 48 h in the presence of anti-CD3/CD28 
beads. Cells were harvested for mRNA extraction and expression of IDO mRNA was analyzed by qRT-PCR.  
β-actin served as housekeeping gene. Representative data of three independent experiments are shown. Bars 
represent mean +/- SD from duplicates. Significant differences were analyzed by one-way ANOVA including 
Bonferroni correction. P-values < 0.05 were considered significant. 
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7 Discussion 
7.1 T110299 cells generated from KPC tumors represent a valuable tool for studying 
PDAC 
Pancreatic cancer research needs clinically relevant mouse tumor models. Since 1984, when Corbett et 
al. described the chemically induced Panc02 cell line, these cells have frequently been used to study 
pancreatic cancer biology and therapy in vitro and in vivo (Corbett et al., 1984). In 2003 and 2005, 
Hingorani et al. published the first GEMM for pancreatic cancer that reflects the human disease in 
many aspects (Hingorani et al., 2003, Hingorani et al., 2005). However, studies on these mouse 
models are laborious, time consuming and therefore not ideally suited for the study on novel 
therapeutic strategies at a large scale. In this respect, the transplantation of tumor cells in syngeneic 
animals, e.g. orthotopically into the pancreas, offers several advantages, such as better controlled 
tumor growth, the possibility to manipulate tumor cells ex vivo (e.g. transfection of the cells with 
specific antigens or constructs that can be used for in vivo imaging), and the availability of knock-out 
animals in order to study the contribution of specific immune-mediated mechanisms to therapy 
success. One option for generating tumor models that more closely reflect the human tumor biology is 
to generate cell lines from KPC mice. This study characterized four PDAC models with regard to 
tumor architecture (tumor cell differentiation, PanIN formation, stroma composition and blood vessel 
formation), T cell infiltration, and the expression pattern of selected immunosuppressive molecules 
like galectin-1 and IDO. The intention of these efforts was to identify the best suited preclinical 
models to investigate the interaction of tumor cells with the immune system as well as other local and 
systemic factors. A functional immune system is a prerequisite for the research on tumor cell 
interactions with cytotoxic T cells, regulatory T cells, tumor-associated macrophages, immune cell 
trafficking or the inflammatory stromal reaction. Furthermore, immune competent models are more 
convenient for therapy studies (Partecke et al., 2011). 
 
Tumors from Panc02 cells revealed a poorly differentiated morphology with a sarcomatoid 
architecture and areas of necrosis, probably due to rapid and uncontrolled tumor growth. Partecke et 
al. previously described that Panc02 tumors have a sarcoma-like undifferentiated growth pattern, 
which is rarely found in humans (Partecke et al., 2011). In contrast, tumors from T110299 cells, which 
were originally derived from KPC mice, were moderate to well-differentiated and exhibited duct-like 
structures typical for adenocarcinoma. Similar results have been reported by Partecke et al., who used 
a cell line derived from a GEMM tumor carrying the KrasG12D mutation with normal p53 expression 
(6606PDA) (Partecke et al., 2011). The morphology showed similarities to primary KPC tumors that 
were investigated in this study. Primary KPC tumors have an accelerated development of metastatic 
well-differentiated PDAC whereas KPfC tumors have an even shorter latency and survival rate, 
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compared to KPC mice (Mazur and Siveke, 2011, Hingorani et al., 2005). Tuveson et al. previously 
reported that the tumors from KPC mice bear a high analogy to human pancreatic cancer in many 
different aspects (histology, pathology, genetics, etc.) (Tuveson and Hingorani, 2005).  
 
Immunohistochemistry studies revealed that Panc02 tumors express very little tumor stroma and, as 
expected, no PanIN lesions (poorly differentiated grade 3 tumor), as shown by Masson`s Trichrome 
and Alcian Blue staining, respectively. This observation exposed a critical weakness of the Panc02 
tumor model, as characteristics of human pancreatic cancers are (1) the high abundance of stroma 
(Chu et al., 2007, Mahadevan and Von Hoff, 2007) and (2) the establishment of adenocarcinomas 
from precursor lesions (Hruban et al., 2008). Both KPC and KPfC tumor models showed abundant 
stroma and PanIN lesions (well differentiated grade 1 tumors). Interestingly, T110299 tumors were 
also had lots of tumor stroma. KPC tumors displayed the papillary structure with many PanIN lesions 
at lower stages whereas KPfC tumors represented PanIN lesions at higher stages and more 
adenocarcinoma structures. In comparison, tumors from the T110299 cell line showed less mucin 
staining, but the areas resembling PanIN lesions were well detectable and indicated that the cell line 
contains cells with various differentiation grades. 
 
In tumors, formation of blood vessels is an important factor for the supply with nutrients and oxygen 
and therefore promotes tumor progression. In pancreatic carcinoma, van der Zee et al. showed that 
tumor growth is less dependent on angiogenesis (van der Zee et al., 2011). In general, the vasculature 
in primary pancreatic cancer in both humans and mouse is sparse (Olive et al., 2009). Orthotopic 
tumors from the Panc02 and T110299 cell lines as well as both KPC tumor models revealed abundant 
blood vessel formation in the periphery of the tumor, but in central regions very few and only distorted 
blood vessels could be found. Some vessels could be noticed around PanIN lesions and 
adenocarcinoma structures. Olive et al. showed that in transplanted tumors, blood vessels arise in close 
proximity to neoplastic cells, leading to a dense vascularization in the periphery. In contrast, in KPC 
mice and human PDAC, blood vessels were widely spaced from cancer cells and the density of blood 
vessels was markedly decreased (Olive et al., 2009). These anatomical features contribute to a barrier 
for drug delivery in PDAC and to the creation of a hypoxic environment (Hidalgo and Von Hoff, 
2012). Whether the leakiness of the vasculature and drug delivery into tumors differs between the 
different tumor models has to be investigated in further studies.  
 
PDAC express a variety of cancer-associated antigens that can potentially be recognized by T cells. 
However, these T cells are often dysfunctional after migration to the tumor site. PDAC has been 
recognized for the development of immune escape mechanisms, like the down-regulation of MHC 
class I molecules and Fas receptor, the recruitment of Tregs and MDSC, the secretion of IL-10 and 
TGF-β, the induction of loss of CD3ζ by T cells (thereby inactivating T cell signaling) and the 
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expression of Fas-ligand on tumor cells to induce apoptosis in cancer-infiltrating effector T cells 
(Kleeff et al., 2007, Lunardi et al., 2013). Contrary to KPC tumors, Panc02 and T110299 tumors were 
significantly more infiltrated with T cells both at the tumor margin as well as in central tumor regions. 
Several other groups reported that in PDAC progression, the infiltration with leukocytes, especially T 
cells and regulatory T cells, increases (Clark et al., 2007, Ryschich et al., 2005, Fukunaga et al., 2004, 
Bazhin et al., 2013, Shevchenko et al., 2013). Regulatory T cells can prevent an immune response 
against the tumor by competitive consumption of IL-2 and the induction of IL-10 and TGF-β (Zou, 
2006). Shevchenko et al. demonstrated in an orthotopic Panc02 tumor model that these tumors were 
highly infiltrated with regulatory T cells with an effector/memory phenotype, suggesting their 
enhanced suppressive activity and higher proliferation capacity (Shevchenko et al., 2013). In KPC 
tumors, it is possible that T cells reach the tumor border attracted by the inflammatory milieu found in 
stroma, but due to the immunosuppressive milieu within the tumor and the fortress built by stromal 
components, only few T cells reach the central tumor regions. A predominant T cell clustering around 
preinvasive lesions has been observed (Clark et al., 2007). The high infiltration with CD3+ T cells in 
Panc02 tumors is largely attributed to regulatory T cells, reaching up to 40% of all T cells within the 
tumor (Jacobs et al., 2011). Similarly, T110299 tumors are infiltrated with regulatory T cells and far 
less with CD8+ T cells (data not shown). A possible reason for higher T cell infiltration in transplanted 
tumors may be seen in the inflammatory milieu created by injecting tumor cells, which causes a 
wound, due to the injection, and cell death at the injection site.  
 
A possible explanation for the reduced numbers of tumor infiltrating T cells could be seen in apoptosis 
induction through the immunosuppressive milieu in pancreatic cancer. A likely candidate for inducing 
T cell apoptosis is Galectin-1 (Kovacs-Solyom et al., 2010, Banh et al., 2011). It has been described 
that galectin-1 in PDAC is expressed by activated PSCs, which are characterized by strong α-SMA 
expression (Tang et al., 2011, Xue et al., 2011). Activated PSCs are located adjacent to and 
surrounding cancer cells whereas in healthy pancreatic tissue PSCs remain in a quiescent state with no 
α-SMA expression. Galectin-1 is strongly expressed in activated PSCs which form a barricade 
between tumor and other stromal compartments (Tang et al., 2011). It was also shown that galectin-1 
expression significantly increased from dysplastic pancreatic tissue to PDAC progression. This could 
also be observed in this study when comparing tumors from KPC and KPfC mice. KPfC tumors 
contain more adenocarcinoma structures correlating with enhanced galectin-1 and α-SMA protein 
expression in stroma. Tumors from the T110299 cell line also revealed a strong galectin-1 and α-SMA 
expression in stromal cells surrounding cancer cells. In contrast, galectin-1 was strongly expressed in 
Panc02 tumor cells. As stroma was virtually absent in Panc02 tumors, collagen and α-SMA staining 
was faint. Tang et al. described that few CD3+ T cells infiltrate in the parenchyma surrounding the 
tumor, correlating with galectin-1 staining in the mesenchymal cell population around the tumor. 
These observations, which are in line with this study, suggest that galectin-1 might comprise an 
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immunological barrier. Banh et al. and Kovás-Sólyom et al. reported that galectin-1 promotes T cell 
apoptosis, tumor growth and metastasis (Banh et al., 2011, Kovacs-Solyom et al., 2010). Galectin-1 
may further contribute to the immunosuppressive microenvironment in PDAC by suppressing 
transendothelial migration of effector T cells to the tumor site (Yang et al., 2008, Cedeno-Laurent and 
Dimitroff, 2011, Toscano et al., 2007). On the one hand, Chen et al. found that lower expression levels 
of stromal galectin-1 in pancreatic cancer patients are a positive prognostic factor (Chen et al., 2012). 
On the other hand, overexpression of galectin-1 has been documented in many different tumor types, 
including breast carcinoma, hepatocellular carcinoma and oral squamous cell cancer, among others, 
and often correlated with tumor aggressiveness and metastatic phenotypes (Daroqui et al., 2007, Spano 
et al., 2010, Zhong et al., 2010).  
 
Another immunosuppressive molecule that was investigated in this study is IDO. IDO was strongly 
expressed in Panc02 tumors but also in non-transformed acinus cells. Witkiewicz et al. reported that 
IDO is expressed in the cytoplasm of well-differentiated pancreatic adenocarcinomas from human cell 
lines but is not expressed in healthy pancreatic tissue (Witkiewicz et al., 2008). In a subsequent study, 
the same authors showed that IDO2 is equally overexpressed and an active target in pancreatic cancer 
(Witkiewicz et al., 2009). In T110299 and both KPC tumor models IDO was expressed in the 
cytoplasm of tumor cells, but was also found in some cells located in the stroma. As IDO is expressed 
by APCs in tumors, those cells might represent infiltrating APCs (Grohmann et al., 2003, Katz et al., 
2008). Further studies are required to better define IDO expressing stromal cells in these tumor 
models.  
 
In summary, the histological results suggest that the Panc02 tumor model differs substantially from the 
majority of human PDAC, whereas KPC models more closely reflect the situation found in human 
pancreatic cancer in regard to stroma production, tumor cell differentiation (including the presence of 
PanINs), as well as expression patterns of Galectin-1 and IDO. The orthotopic T110299 tumor model 
may be a valuable tool for the research on novel treatments for PDAC. Tumor growth is very reliable 
and homogeneous. In addition, tumor cell morphology, tumor stroma and the expression of 
immunosuppressive molecules closely resemble primary tumors in KPC mice, and thus the human 
disease.  
7.2 Treatment with 5’ppp-modified siRNA targeting galectin-1 prolongs survival in 
the Panc02 tumor model 
Pancreatic cancer is mostly diagnosed at an advanced stage. Therefore, surgical resection can be 
performed in only a small number of patients and even after resection, recurrence occurs in the 
majority of the patients. Although adjuvant treatment with both chemotherapy and radiation therapy 
Discussion 
78 
has been investigated demonstrating some improvements in disease-free and overall survival rates, 
new therapeutic approaches are urgently needed (Koido et al., 2011). 
The aim of cancer immunotherapy is to activate the immune system for therapeutic benefit. Immune 
responses against viruses and tumors share common principles, such as T cell-mediated killing of 
target cells and immune evasion. A strategy for tumor immunotherapy could be to mimic a viral 
infection for boosting immunity against the tumor cells. In this study, a combination of two antiviral 
principles was used to treat experimental pancreatic cancer. Firstly, a sequence specific degradation of 
mRNA by RNAi; and secondly, the activation of the pattern recognition receptor RIG-I to initiate a 
type I IFN driven immune response. This study could confirm RIG-I receptor expression in PDAC 
cells (Ellermeier et al., 2013). Both murine cell lines, Panc02 and T110299, up-regulated RIG-I 
expression when stimulated with type I IFNs, but Panc02 cells were more sensitive in this respect. 
Upon RIG-I activation with ppp-RNA, Panc02 tumor cells secreted high levels of CXCL10, a 
chemokine attracting lymphocytes, and up-regulated IFN-β expression. In addition, the surface 
expression of MHC-I molecules was induced. Thus, intratumoral RIG-I activation has the potential to 
attract lymphocytes to the tumor site and to activate TH1 cells and cytotoxic T cells for more efficient 
tumor cell killing. In contrast, T110299 cells transfected with ppp-RNA secreted lower levels of 
CXCL10 and no IFN-β and MHC-I up-regulation was observed. Moreover, the phosphorylation of the 
transcription factor IRF3 and the induction of apoptosis was seen in Panc02 but not T110299 cells, 
indicating that RIG-I signaling is defective in this cell line derived from KPC mice. Further studies are 
needed to assess whether RIG-I signaling is defective in all tumor cell lines derived from the KPC 
model, or whether this a unique feature of this particular cell line. This is an important issue regarding 
the choice of the best-suited tumor model for immunotherapy studies. Of note, all human PDAC cell 
lines tested so far do express functional RIG-I and undergo apoptosis in response to ppp-RNA 
treatment (Ellermeier et al., 2013).  
 
Next, this study evaluated a novel bifunctional ppp-siRNA silencing galectin-1 for the treatment of 
murine pancreatic cancer. The treatment of Panc02 and T110299 tumor cells with ppp-Gal-1 revealed 
an efficient knockdown of galectin-1 expression reaching similar levels as an unmodified OH-Gal-1 
siRNA. However, as described for the control ppp-RNA RIG-I mediated effects, such as IFN-β 
production, MHC-I up-regulation and apoptosis induction, were only observed in Panc02, but not 
T110299 cells.  
 
Therefore, these in vitro results guided us to explore ppp-Gal-1 based immunotherapy in the Panc02 
tumor model in vivo. Interestingly, in mice with Panc02 tumors galectin-1 serum levels correlated with 
tumor size, indicating that galectin-1 is tumor derived, or at least induced by the tumor. 
Disappointingly, the systemic treatment of these mice with OH-Gal-1 had no significant influence on 
galectin-1 expression in tumor tissue. A reason for this failure might be that the treatment was either 
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too short or, more likely, that RNA levels deposited at the tumor site were too low. New strategies 
optimizing siRNA delivery to the tumors are warranted and are the focus of future studies in our 
working group. However, galectin-1 serum levels decreased upon treatment, although statistical 
significance was not reached. Whether this decrease of galectin-1 levels reflects true RNAi-mediated 
silencing in the tumor or simply reduced viability of the tumor cells, which seem to be the main source 
of galectin-1 production in the Panc02 model, remains an open question. In the survival experiment 
the systemic treatment with OH-Gal-1 and ppp-Gal-1 included a total of six injections over the course 
of three weeks. The treatment with OH-Gal-1 showed no significant effect on tumor-specific survival 
(35 days) whereas ppp-Gal-1 extended median survival up to 49 days. Maybe even more importantly, 
20% of the mice rejected their tumor and had no signs of residual tumor mass after an observation 
period of 100 days. Thus, ppp-Gal-1 appears to be a highly effective novel molecule for the treatment 
of murine pancreatic cancer. No significant toxicity was observed during treatment with ppp-Gal-1, 
indicative of a broad therapeutic window (data not shown). These results are in line with a previous 
report from our group in which systemic treatment with ppp-RNA targeting TGF-β induced effective 
tumor cell apoptosis in vivo, whereas normal pancreas or other organs showed no signs of 
histopathology (Ellermeier et al., 2013). A likely reason for low toxicity is the observation that tumor 
cells are highly susceptible to RIG-I mediated apoptosis whereas non-malignant cells are protected via 
Bcl-xL expression (Besch et al., 2009, Meng et al., 2013). Another possibility is an enhanced CD95 
(Fas) expression of tumor cells exposed to ppp-RNA rendering them sensitive towards killing via Fas-
FasL interaction by activated lymphocytes ((Meng et al., 2013) and own unpublished observations). A 
long-term survival of some of the ppp-Gal-1 treated mice is indicative that RIG-I-based treatment 
induces a tumor-specific adaptive immune response leading to efficient tumor control. In a follow-up 
study, our group could demonstrate that RIG-I activation induces immunogenic tumor cell death 
resulting in efficient antigen uptake and presentation by DCs. As a result, CD8+ T cells acquire a 
killing function leading to further antigen release in the tumor and thereby entertaining an anti-tumor 
immunity cycle (Duewell et al., manuscript submitted).  
 
Together, these data suggest that treatment with ppp-Gal-1 is a new valuable strategy for 
immunotherapy of PDAC, deserving further evaluation, e.g. in the KPC tumor model. As galectin-1 is 
highly expressed in the tumor stroma of KPC mice, ppp-Gal-1 therapy may contribute to the reduction 
of tumor stroma. Tumor stroma has recently been identified as an interesting target for treatment of 
PDAC (Neesse et al., 2011). In this regard, it will be of interest to assess whether PSC are susceptible 
to RIG-I mediated apoptosis and the extent of PSC-mediated immune suppression. Further 
improvements of this ppp-siRNA strategy are urgently needed, such as a large-scale synthetic 
generation of the 5’ppp-modification to avoid in vitro transcription via the T7 polymerase and RNA 
formulation tools for more effective RNA delivery into the tumors. In addition, combination therapies 
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with chemotherapy are currently being investigated by our group for enhancing therapeutic efficacy of 
ppp-RNA-based immunotherapy.  
7.3 Murine pancreatic cancer cells induce potent T cell inhibition via TGF-β and IDO  
Several reports by independent groups have found that T cells infiltrating PDAC are dysfunctional 
through a variety of immunosuppressive mechanisms present in the tumor microenvironment (Kleeff 
et al., 2007, Lunardi et al., 2013). This study now shows that the proliferation of both CD4+ and CD8+ 
T cells was significantly inhibited through soluble factors present in the tumor supernatant of Panc02 
and T110299 cell lines in vitro. T cell suppression was highly effective, since addition of as little as 
1% of tumor supernatant to complete T cell media led to a 50% reduction of the T cell proliferative 
response mediated by CD3 and CD28 ligation. Naïve T cells also underwent apoptosis whereas 
effector functions, such as degranulation of cytotoxic CD8+ T cells, were not impaired. To characterize 
the mechanisms leading to T cell inhibition in PDAC, this study investigated different soluble or 
secreted factors that are capable of impairing T cell proliferation. 
 
T cell homeostasis is critical for an intact immune system and is regulated by different mechanisms. 
Two naturally occurring “T cell brakes” are CTLA-4 and PD-1 expressed by T cells, which bind to 
B7-1 (CD80/CD86) and PD-L1 (CD274/B7-H1) on APCs, respectively (Chen and Flies, 2013, Butte 
et al., 2007). Freeman et al. reported that PD-L1 reduced T cell proliferation when co-immobilized on 
plastic beads with anti-CD3 mAb (Freeman et al., 2000). Latchman et al. found that PD-1/PD-L1 
signals inhibited T cell proliferation by blocking cell cycle progression but not by increasing cell death 
(Latchman et al., 2001). Then again, others showed that PD-L1 can be expressed by cancer cells 
leading to apoptosis of activated T cells (Dong et al., 2002). The expression of PD-L1 on murine and 
human pancreatic cancer cell lines has been reported (Okudaira et al., 2009, Nomi et al., 2007). 
Notably, the expression of PD-L1 can be induced by IFN-γ, a cytokine thought to have anti-tumor 
activity. Frigola et al. identified a soluble form of PD-L1 in cell-supernatants of PD-L1-positive tumor 
cell lines that retains immunosuppressive activity (Frigola et al., 2011). The same group could 
demonstrate that soluble PD-L1 induced apoptosis in CD4+ and CD8+ T cells (Frigola et al., 2012). 
These observations prompted us to investigate the presence of soluble PD-L1 in tumor supernatant of 
Panc02 and T110299 cells. Both cell lines expressed PD-L1 on the cell surface and PD-L1 protein was 
found in the supernatants of the tumor cells. However, neutralizing PD-1 expressed on T cells using an 
anti-PD-1 mAb did not influence the T cell inhibitory effect mediated by tumor supernatants T cell 
proliferation, indicating that other mechanisms than the PD-1/PD-L1 axis are likely to be more 
important.  
 
Immunosuppressive prostanoids, especially prostaglandins, are other possible tumor-derived factors 
leading to T cell inhibition. Prostanoids are generated by the enzymes cyclooxygenase 1 and 2 (COX1 
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and 2). COX1 is constitutively expressed by many cell types and plays an active role in colon 
carcinogenesis (Wu et al., 2009), while COX2 is usually induced and overexpressed in pancreatic 
cancers, possibly playing a role in tumor progression (Colby et al., 2008, Hill et al., 2012). Here, 
selective inhibitors for COX1 (SC-560) and COX2 (Celecoxibe) were used to treat pancreatic cancer 
cell lines before tumor supernatant was collected for T cell proliferation assays. Neither COX1 nor 
COX2 inhibition had a significant influence on the T cell suppressive effect of tumor supernatants, 
suggesting that prostanoids are not involved in this phenomenon.  
 
A focus of this study was galectin-1, which can overwhelm T cell effector functions by modulation of 
effector T cell survival (Rubinstein et al., 2004). Perillo et al. and other groups showed that galectin-1 
inhibits T cell activation, induces growth arrest and apoptosis of activated T cells, mainly TH1, TH17 
and CD8+ T cells (Rabinovich et al., 2002, Perillo et al., 1995, Salatino et al., 2008, Kovacs-Solyom et 
al., 2010, Banh et al., 2011) and suppresses the secretion of pro-inflammatory cytokines (IL-2, TNF-α, 
IFN-γ) leading to a TH2 cytokine profile (Rabinovich et al., 1999, Salatino et al., 2008). The induction 
of regulatory T cells is another mechanism how secreted galectin-1 promotes an immunosuppressive 
milieu in tumors (Ito et al., 2012, Garin et al., 2007). Galectin-1 is expressed in various cancer cell 
types like pancreatic cancer, breast cancer, glioma, colon carcinoma and thyroid carcinoma, but also in 
non-malignant cells, such as PSC (Satelli et al., 2008, Dalotto-Moreno et al., 2013, Xue et al., 2011, 
Chen et al., 2012). Immunohistochemistry demonstrated the expression of galectin-1 in both Panc02 
and T110299 cell lines. Furthermore, the galectin-1 content in cell lysates and supernatants from both 
tumor cell lines supported the hypothesis that galectin-1 may be responsible for inducing T cell 
inhibition in the T cell proliferation assays. Surprisingly, neither silencing of galectin-1 via siRNA nor 
inhibition with β-lactose or TDG had a significant effect on T cell inhibition by tumor supernatants. 
These results are in contrast to reports by other groups which could show that galectin-1 silencing and 
inhibitors alter T cell inhibition (Dalotto-Moreno et al., 2013, Tang et al., 2011, Ito and Ralph, 2012, 
Ito et al., 2011). Based on these experiments one has to conclude that other factors present in the 
tumor supernatant of PDAC cells are far more effective T cell suppressors than galectin-1. In contrast, 
these in vitro experiments were not designed to rule out a role for galectin-1 in T cell inhibition at the 
tumor site in vivo, as induction of T cell apoptosis may require intimate cell-cell contact between 
tumor cells and T cells for translocation of tumor cell-bound galectin-1 to T cells (Kovacs-Solyom et 
al., 2010). 
 
Our group recently reported that murine pancreatic cancer cells produce high levels of TGF-β and that 
serum levels were significantly increased in Panc02-tumor-bearing mice (Ellermeier et al., 2013). 
TGF-β is well known for causing immunosuppression by inducing (1) regulatory T cells from CD4+ T 
cells and (2) apoptosis in T effector cells, (3) inhibiting cytokine production of cytotoxic T cells and 
(4) down-regulating IL-2R on T cells (de Visser and Kast, 1999, Rubtsov and Rudensky, 2007). Thus, 
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TGF-β is a likely candidate for mediating the observed T cell suppression in proliferation assays. To 
investigate this, TGF-β1 was transiently silenced via siRNA in tumor cells. However, TGF-β1 silencing 
did not restore T cell proliferation. Possible explanations could be an insufficient silencing activity of 
the siRNA (50-80%) or that other isoforms of TGF-β (e.g. TGF-β2) are compensating for reduced 
TGF-β1 levels. To rule these possibilities out, the small molecule inhibitor SD-208 was used in T cell 
proliferation assays. SD-208 is a potent 2,4-disubstitued pteridine, ATP-competitive TGF-β-RII kinase 
inhibitor that blocks the biological effects of both TGF-β1 and TGF-β2 (Uhl et al., 2004). Gaspar et al. 
previously demonstrated that SD-208 blocks TGF-β dependent Smad2 phosphorylation and expression 
of TGF-β inducible proteins in pancreatic cancer cells, leading to reduced tumor growth and decreased 
incidence of metastasis (Gaspar et al., 2007). Interestingly, T cell proliferation was significantly 
restored when TGF-β signaling was blocked in T cells by SD-208. The T cells also secreted more pro-
inflammatory cytokines, such as IFN-γ (data not shown), in line with observations made by Uhl et al. 
(Uhl et al., 2004). Thus, SD-208 treatment has potential for rescuing T cell proliferation in pancreatic 
cancer. Nonetheless, T cell proliferation was only partially restored by SD-208, suggesting that other 
factors in tumor supernatant significantly contribute to T cell inhibition.  
 
Another potentially interesting factor leading to T cell inhibition is IDO. IDO is highly expressed in 
pancreatic cancer and its activity can be further induced by IFN-γ (Lee et al., 2002, Johnson et al., 
2009, Katz et al., 2008). To investigate the contribution of IDO in regard to T cell inhibition, 1-
methyl-tryptophan (1-MT), a specific, competitive inhibitor of IDO, was used. 1-MT had been applied 
in many studies to reveal IDO-mediated effects both in vitro and in vivo (Johnson et al., 2009). Here 
the D-isomer was chosen because it is more effective in reversing IDO-mediated suppression of 
effector T cell responses in vitro and slowing the growth of transplantable tumors in mice via T cell-
dependent mechanisms (Johnson et al., 2009). This study revealed that tumor supernatant from Panc02 
and T110299 cell lines induced IDO mRNA expression in T cells and that D-1-MT significantly 
restored T cell proliferation. Interestingly, the inhibitory effect was more pronounced when D-1-MT 
was given to T cells as compared to the tumor cells, indicating that T cell-derived or soluble tumor-
derived IDO was mainly responsible for the inhibitory effect on T cell proliferation. Furthermore, T 
cell viability significantly increased when IDO was blocked in T cells. Remarkably, this effect 
correlated with reduced Fas (CD95) expression on cytotoxic T cells. These results point towards a 
factor in the tumor supernatant of Panc02 and T110299 cells that induces IDO expression in T cells, 
which finally leads to apoptosis of T cells in an autocrine or paracrine manner. IDO enzyme activity 
leads to the production of kynurenine as a result of tryptophan metabolism. N-formyl-kynurenine is 
hydrolyzed to kynurenine, which inhibits protein biosynthesis and induces T cell apoptosis (Mellor 
and Munn, 1999). Known inducers of IDO are prostaglandin E2 (PGE-2) (Muller and Prendergast, 
2007), IFN-γ (Taylor and Feng, 1991), LPS (TLR4 ligand), CpG ODN (TLR9 ligand) (Johnson et al., 
2009) and TGF-β (Yuan et al., 1998, Fallarino et al., 2012). PGE-2 is produced by COX2; as 
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Celecoxibe had no effect on T cell inhibition, it is unlikely that PGE-2 is the inducer of IDO 
expression in T cells. INF-γ can also be ruled out as pancreatic tumor cells do not express this T cell 
derived cytokine. Similarly, TLR ligands released by tumor cells are also unlikely in this regard, but 
were not ruled out in this study. Finally, TGF-β has been shown to influence IDO activity. Fallarino et 
al. reviewed the interaction of IDO and TGF-β concluding that IDO responds to TGF-β by regulating 
gene transcription thereby amplifying its expression and maintaining a TGF-β-dominated environment 
(Fallarino et al., 2012). Thus, tumor derived TGF-β (and possibly other secreted factors) may induce 
IDO expression in T cells, thereby leading to autointoxication of T cells by kynurenine and 
subsequently T cell apoptosis. The blocking of TGF-β signaling by SD-208 may intervene here to stop 
amplification of IDO expression in T cells, thus rescuing T cells from apoptosis. This hypothesis has 
to be investigated in further experiments, which are currently conducted in our working group. 
Combinatorial therapy with SD-208 and D-1-MT may be a promising treatment strategy for pancreatic 
cancer that deserves further investigation in preclinical models of PDAC. 
7.4 Conclusion and perspectives 
This study provides evidence that the T110299 model, which is derived from the KPC tumor model, 
shares many histological features with both spontaneous tumors arising in KPC mice and human 
tumors. Especially the typical appearance of glandular structures resembling adenocarcinoma, the 
pronounced stroma production and poor vascularization in the center of the tumor make this cell line a 
valuable tool to study novel therapies for PDAC in which the tumor stroma is a therapeutic target. In 
addition, IDO and TGF-β expression by the tumor cells, and galectin-1 expression in PSC in the 
stroma make this model ideally suited to investigate immunosuppressive mechanisms, which are also 
active in human PDAC. However, defective RIG-I signaling in T110299 cells is an obstacle for 
studying RIG-I-based immunotherapies in this model. Here, the Panc02 tumor model appears to be the 
more suitable option, as this cell line expresses functional RIG, which is also the case in all tested 
human PDAC cell lines (Ellermeier et al., 2013). Interestingly, recent studies in our group could 
demonstrate that T110299 cells express functional MDA-5, another cytosolic helicase involved in 
viral recognition and immune signaling. MDA-5 ligands induced type I IFN production and mediated 
tumor cell apoptosis (Hannes Hölz, personal communication). Therefore, therapy with MDA-5 ligands 
could be investigated in this mouse model. Taken together, a detailed understanding of morphological 
and biological characteristics of the different tumor models is vital for the choice of the right 
preclinical model in order to address scientific questions, such as therapy response or immune 
suppressive mechanisms. 
 
For immunotherapy of PDAC a bifunctional siRNA combining RNAi-mediated gene silencing of 
galectin-1 with ppp-RNA-mediated RIG-I activation (ppp-Gal-1) was designed, produced by in vitro 
transcription using the T7 polymerase and evaluated in the orthotopic Panc02 tumor model. The dual 
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activities of this molecule were confirmed in vitro, leading to reduced galectin-1 expression, 
production of CXCL10 and IFN-β, MHC-I up-regulation and apoptosis of tumor cells. The treatment 
of mice with orthotopic pancreatic tumors with ppp-Gal-1 significantly prolonged survival, as 
compared to unmodified OH-Gal-1 or control RNA. In addition, 20% of the mice rejected their tumors 
completely leading to long-term tumor control. Thus, 5’ppp-modified siRNA is a promising treatment 
strategy for PDAC, as previously shown for a ppp-siRNA targeting the immunosuppressive molecule 
TGF-β1 or glutaminase, an enzyme critically involved in tumor cell metabolism and ROS elimination 
(Ellermeier et al., 2013, Meng et al., 2013). To push this novel strategy into the realm of clinical 
testing, further improvements have to be achieved. These include identifying delivery systems for 
optimal RNA cargo deposition in the tumor, optimal dosing and injection routes, and synthetic 
generation of 5’ppp-modified siRNA on a large scale under GMP conditions. GEMM, such as the 
KPC model, and derived cell lines may be helpful for future developments.   
 
Pancreatic tumor cells employ multiple mechanisms for suppression of T cell responses. This study 
identified TGF-β and IDO as two potent and drugable inhibitors of T cell proliferation. Supernatants 
of PDAC cells effectively blocked T cell proliferation induced by CD3 and CD28 triggering. This 
could be partially prevented by the inhibition of TGF-β receptor signaling via SD-208 or by blocking 
IDO activity with D-1-MT. An interesting observation was that tumor supernatant induced 
pronounced up-regulation of IDO mRNA expression in T cells. Furthermore, blocking IDO activity in 
T cells appeared to be more effective than blocking IDO in tumor cells. This leads to a new hypothesis 
that factors secreted by the tumor cells (such as TGF-β) induce IDO expression in T cells, which in 
turn leads to autointoxication of the T cells via kynurenine production and eventually T cell apoptosis. 
This suicide or paracrine-mediated fratricide can potentially be prevented by either blocking TGF-β 
receptors, IDO or both. Nonetheless, this hypothesis needs to be confirmed in relevant in vitro and in 
vivo systems. 
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9 Appendices 
9.1 Abbreviations 
AEC  3-Amino-9-ethylcarbazole 
AHR  Aryl hydrocarbon receptor 
APC  Allophycocyanin 
APCs  Antigen presenting cells 
 
BMDCs Bone marrow-derived dendritic cells 
BRCA2 Breast cancer type 2 susceptibility protein 
 
CAR  Chimeric antigen receptor 
CCL  Chemokine (C-C motif) ligand 
CD  Cluster of differentiation 
cDC  Conventional dendritic cell 
cDNA  Copy deoxyribonucleic acid 
CDNK2A Cyclin-dependent kinase inhibitor 2A 
CEA  Carcinoembryonic antigen 
CFSE  Carboxyfluorescein diacetat succinimidyl ester 
CK 19  Cytokeratin 19 
COX1/2 Cyclooxygenase 1/2 
CTL  Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
CXCL  Chemokine (C-X-C motif) ligand 
 
DAB  3,3’-diaminobenzidine 
DAPI  4',6-diamidino-2-phenylindole 
DC  Dendritic cell 
D-1-MT D-1-methyltryptophan 
DMEM  Dubelcco’s Modified Eagle Medium 
DMSO  Dimethyl sulfoxide 
DTT  Dithiotreitol 
 
ECM  Extracellular matrix 
EFG  Epidermal growth factor 
ELISA  Enzyme-linked immunosorbent assay 
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FACS  Fluorescence activated cell sorter 
FBS  Fetal bovine serum 
FITC  Fluorescein isothiocyanate 
FoxP3  Forkhead box P3 
FRET  Fluorescence resonance energy transfer 
 
Gal-1  Galectin-1 
GEMM  Genetically engineered mouse model 
GM-CSF Granulocyte macrophage-colony stimulating factor 
 
H&E  Hematoxylin and eosin 
HLA  Human leukocyte antigen 
HPF  High power field 
HPRT  Hypoxanthin-phosphoribosyl-transferase 
HRP  Horse radish peroxidase 
 
IDO  Indoleamine 2,3-dioxygenase 
IFN  Interferon 
Ig  Immunoglobulin 
IHC  Immunohistochemistry 
IL  Interleukin 
i.p.  Intraperitoneal 
IPMN  Intraductal papillary mucinous neoplasm 
IP-10  Interferon gamma induced protein 10 
IPS-1  Interferon beta promoter stimulator 1 
IRF-3  Interferon regulatory factor 3 
i.t.  Intratumoral 
i.v.  Intravenous 
 
KD  Knockdown 
Kras  V-Ki-ras 2 Kirsten rat sarcoma viral oncogene homolog 
 
LPS  Lipopolysaccheride 
LSL  Lox-Stop-Lox 
 
mAb  Monoclonal antibody 
3-MCA  3-Methylcholantren 
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MCN  Mucinous cystic neoplasm 
MDA-5 Melanoma differentiation-associated protein 5 (RIG-I-like helicase) 
MDSC  Myeloid-derived suppressor cells 
MFI  Median fluorescence intensity 
MHC  Major histocompatibility complex 
MMP  Matrix metalloproteinase 
mRNA  Messenger RNA 
 
NAD  Nicotinamide adenine dinucleotide 
NK cell Natural killer cell 
NLR  Nod-like receptor 
 
PAMPS Pathogen-associated molecular patterns 
PanIN  Pancreatic intraepithelial neoplasia 
PB  Pacific blue 
PBS  Phosphate buffered saline 
PD-1  Programmed cell death protein 1 
PDAC  Pancreatic ductal adenocarcinoma 
pDC  Plasmacytoid dendritic cell 
PDGF  Platelet-derived growth factor 
PD-L1  Programmed cell death ligand 1 
PE  Phycoerythin 
PerCP  Peridinin chlorophyll 
PFA  Paraformaldehyde 
PI  Propidium iodide 
ppp  Triphosphate 
PSC  Pancreatic stellate cell 
 
qRT-PCR Quantitative real time PCR 
 
RIG-I  Retinoic acid-inducible gene-I 
RISC  RNAi-induced silencing complex 
RNA  Ribonucleic acid 
RNAi  RNA interference 
RPMI  Roswell Park Memorial Institue 
 
s.c.  Subcutaneous 
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SDS  Sodium dodecyl sulfate 
siRNA  Small interfering RNA 
α-SMA  Alpha-smooth muscle actin 
SMAC  Supramolecular activation cluster 
 
TAA  Tumor-associated antigen 
TAM  Tumor-associated macrophages 
TBST  TRIS-buffered saline with Tween 20 
TCR  T cell receptor 
TDG  Thiodigalactoside 
TGF-β  Transforming growth factor β 
TH cells T helper cells 
TIL  Tumor infiltrating lymphocyte 
TLR  Toll-like receptor 
TMB  3,3’ 5,5’ Tetramethyl benzidine 
TNF-α  Tumor necrosis factor alpha 
Treg  Regulatory T cell 
 
VEGF  Vascular endothelial growth factor 
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